Document:

License Agreement

 Exhibit 10.42 
 LICENSE AND DEVELOPMENT AND MANUFACTURING TECHNOLOGY TRANSFER AGREEMENT 

This Exclusive License and Development and Manufacturing Technology Transfer Agreement (this “Agreement”), effective as
of the date of the last signature hereto (the “Effective Date”), is made by and between Agenus Inc., a Delaware corporation having offices at 3 Forbes Road, Lexington, MA 02421 (“Agenus”), and NewVac Ltd., a limited
liability company established under Russian laws, with offices at 2a-1, Rabochaya St., Khimki, Moscow 141400 Russia (“Licensee”). Agenus and Licensee are each referred to herein as a “Party” and collectively, as the
“Parties”. 
 RECITALS 
 WHEREAS, Agenus is in the business of developing novel products for the prevention and treatment of cancers and infectious diseases, and has proprietary rights in a product approved in the Russia
Federation for the prevention of the recurrence of adjuvant renal cell carcinoma; 
 WHEREAS, Licensee is in the business of
developing, manufacturing and commercializing novel products in the Russian Federation and is interested in collaborating with Agenus for the further development and commercialization of the Agenus product. 

NOW THEREFORE, in consideration of the foregoing premises, the following mutual promises and covenants and other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows: 
 ARTICLE I

 Definitions 
 When used in this Agreement, each of the following terms shall have the meanings as set forth in this Article I. 
 1.1 “Agenus Product” means HSPPC-96 vaccine, also known as vitespen, and also known as Oncophage® vaccine for the adjuvant treatment of renal cell carcinoma, as defined in the Registration Certificate attached in the Exhibit B. 

  
 [**] = Portions of this
exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

 1.2 “Agenus Product Requirements” means the amount of Agenus Product which Licensee and its
Sublicensees require pursuant to the provisions hereof for commercialization of Agenus Product pursuant to this Agreement and the research and development of the Combination Product pursuant to this Agreement. 

1.3 “Affiliate” means any corporation or other entity that controls, is controlled by, or is under common control with, a Party. For
purposes of this Section 1.3, an entity shall be regarded as in control of another corporation or entity if it owns or directly or indirectly controls more than 50% of the voting securities or other ownership interest of the other corporation
or entity. 
 1.4 “Biomaterial” means a tumor tissue specimen collected for use in manufacturing Agenus Product. 

1.5 “cGMPs” means the applicable current Good Manufacturing Practices for Finished Pharmaceuticals pursuant to 21 C.F.R. 210 et seq., as
amended from time to time, or its equivalent in the Russian Federation or such other equivalent in the applicable territory within the Territory. 
 1.6 “CMO” means a contract manufacturing organization. 
 1.7 “Development
Indication” shall mean the Licensed Indication, or such other indication(s) as may be agreed to in writing between the Parties. 
 1.8
“Development Plan” has the meaning set forth in Section 4.1(b). 
 1.9 “Combination Product” means Agenus
Product combined with Licensee Product whether administered together or via different routes of administration and/or at different sites or times. 
 1.10 “Commercialization Plan” has the meaning set forth in Section 4.1(b) 

1.11 “Control” or Controlled” means with respect to any material, item of information or intellectual property right, the
possession, whether by ownership, license or otherwise, of the right to grant a license, sublicense or other right with respect thereto. 
 1.12
“Developments” has the meaning set forth in Section 11.1(b). 
 1.13 “First Commercial Sale” means on a
country-by-country basis the date of first commercial sale of such product in such country pursuant to this Agreement. 

  
 [**] = Portions of this
exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

 1.14 “Gross Sales” means the amount billed or invoiced on arms-length sales by Licensee,
its Sublicensees or distributors to Third Parties. 
 1.15 “Licensed Indication” means the adjuvant treatment of renal cell
carcinoma in patients at intermediate risk of recurrence. 
 1.16 “Licensed Know-how” means (a) the Manufacturing
Technology, and (b) any other materials, data, results, formulae, designs, specifications, methods, processes, improvements, techniques, ideas, discoveries, technical information, process information, clinical information and any other
information, whether or not any of the foregoing is patentable, which is known to, and is Confidential Information and proprietary to, Agenus and Controlled by Agenus, to the extent that any of the foregoing (i) is necessary or reasonably
useful to make, have made, use or sell the Agenus Product in the Licensed Indication in accordance with this Agreement, or (ii) is otherwise necessary or reasonably useful for the use of Agenus Product in connection with the research,
development, manufacture or use of the Combination Product in the Development Indication in accordance with this Agreement. 
 1.17
“Licensed Patent Rights” means any and all patent applications and patents (including inventor’s certificates and utility models) throughout the world, including any substitutions, extensions, reissues, reexaminations,
renewals, divisions, continuations and continuations-in-part of the foregoing, Controlled by Agenus (regardless of any royalty or other payments to a Third Party required of Agenus), necessary or reasonably useful for the development, manufacture,
use, sale offer for sale or importation of the Agenus Product or the Combination Product. The “Licensed Patent Rights” existing as of the Effective Date are listed on Exhibit A attached and incorporated into this Agreement.

 1.18 “Licensee Product” means Istradefyllin as a co-adjuvant. 
 1.19 “Manufacturing Capacity” means the capacity of the Agenus manufacturing facility in Lexington, MA USA to make Agenus Product for Licensee hereunder, taking into account Agenus’
other manufacturing & on-going compliance requirements, financial resources, staffing and capital equipment considerations, as of January 31, 2012, or such other capacity as may be agreed to between the Parties from time to time.

 1.20 “Manufacturing Technology” means materials, data, results, formulae, designs, specifications, methods, processes,
improvements, techniques, ideas, discoveries, technical information, process information, clinical information and any other information, whether or not any of the foregoing is patentable, which is known to and is Confidential Information and
proprietary to Agenus and is Controlled by Agenus, solely to the extent that any of the foregoing is necessary or reasonably useful for the manufacture of the Agenus Product for the Licensed Indication and Development Indication in accordance with
the Specifications and Agenus standard operating procedures as of the Effective Date, as further defined in the Technology Transfer Plan. 

  
 [**] = Portions of this
exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

 1.21 “Net Sales” means with respect to the Agenus Product, or the Combination Product, as
the case may be, the Gross Sales of such Agenus Product or Combination Product minus the following items to the extent such items are incurred, taken or borne by the seller thereof and do not exceed reasonable and customary amounts in the market in
which such sale occurred: (a) trade, cash or quantity discounts; (b) credits or allowances given or made for rejection or approved return of goods; (c) taxes or government charges, duties or tariffs (other than an income tax) levied
on the sale, transportation or delivery of such Agenus Product or Combination Product. Sales between Licensee and its Sublicensees or its distributors shall be excluded from the computation of Net Sales except where such Sublicensees are the end
users, but Net Sales shall include the subsequent final sales to Third Parties by such Sublicensees, or distributors. 
 1.22
“Pre-existing Intellectual Property” shall have the meaning set forth in Section 11.1(a). 
 1.23 “Price”
shall have the meaning set forth in Section 3.2. 
 1.24 “Production Milestone” has the meaning set forth in
Section 12.2(a). 
 1.25 “Production Milestone Deadline” has the meaning set forth in Section 12.2(b). 

1.26 “Registration Certificate” has the meaning set forth in Section 6.1(a). 

1.27 “Regulatory Approval” means any approval of any applicable Regulatory Authority necessary for the marketing and sale of a
pharmaceutical product in any country or regulatory jurisdiction in the Territory, including, if applicable, any separate pricing or reimbursement approvals that may be required in any country or regulatory jurisdiction in the Territory. 

1.28 “Regulatory Authority” means any federal, national, multi-national, state, provincial or local regulatory agency, department,
bureau or other governmental entity with authority over the marketing or sale of pharmaceutical products. 
 1.29 “Regulatory
Materials” means regulatory applications, submissions, notifications, registrations, Regulatory Approvals, including the Registration Certificate, and/or other filings made to or with a Regulatory Authority that are necessary or reasonably
desirable in order to research, develop, manufacture, receive Regulatory Approval or market and distribute the a pharmaceutical product in a particular country or regulatory jurisdiction. 
 1.30 “Specifications” shall mean the product release specifications for the Agenus Product, whether sold as Agenus Product or as part of the Combination Product, as defined in Exhibit
C. 
 1.31 “Sublicensee(s)” means a party granted a sublicense of the licenses granted pursuant to Section 2.1 of this
Agreement, whether such party is an Affiliate or Third Party. 

  
 [**] = Portions of this
exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

 1.32 “Supply Opt Out” has the meaning set forth in Section 12.3. 

1.33 “Supply Period” has the meaning set forth in Section 12.3. 
 1.34 “Technology Transfer Plan” has the meaning set forth in Section 12.1. 

1.35 “Term” is defined in Section 10.1. 
 1.36 “Territory” means the countries listed on Exhibit D. 
 1.37
“Third Party” means any party other than a Party, their respective Affiliates or a Sublicensee. 
 1.38 “Valid
Claim” means a claim in an issued, unexpired patent, or a claim of a pending patent application, in the Licensed Patent Rights, which has not been held invalid, unpatentable or unenforceable in an unappealed or unappealable decision of a
court or other governmental body of competent jurisdiction, which has not been rendered unenforceable through disclaimer or otherwise, and which has not been lost through an interference or other proceeding, provided that if any pending patent
application is pending for more than [**] years, it shall cease to be within the definition of Valid Claim unless and until it issues. 
 ARTICLE II 
 Licenses 

2.1 Grant of License Rights to Licensee. Subject to the terms and conditions of this Agreement, Agenus hereby grants to Licensee an exclusive
license within the Territory to use and practice the Licensed Know-how and Licensed Patent Rights: (a) to make, have made, use, sell, offer for sale, and import Agenus Product for the Licensed Indication in the Territory; and (b) to make,
have made and use Agenus Product solely to research, develop, make, have made, use, sell, offer for sale and import Combination Products for the Development Indication in the Territory solely in accordance with the Development Plan. In no event
shall Licensee, its Sublicensees, or any CMO acting at Licensee’s or its Sublicensees’ instruction, practice the Licensed Patent Rights or Licensed Know-how for purposes other than as set forth above. In no event shall Licensee have the
right to manufacture or have manufactured the Agenus Product outside of the Specifications without the prior written consent of Agenus. 
 2.2
Sublicenses. Licensee shall have the right (a) to grant sublicenses of its rights under this Agreement with respect to Agenus Product and/or Combination Product, and/or (b) to engage a CMO approved pursuant to Section 12.2(d)
for purposes of manufacturing the Agenus Product for use alone or in the Combination Product, in each case, solely with the prior written consent of Agenus. Licensee shall promptly notify Agenus of the execution of

  
 [**] = Portions of this
exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

 
each Sublicense or CMO arrangement and shall provide Agenus with a copy of the same. Licensee and each Sublicensee or CMO shall enter into a written sublicense agreement subject to, consistent
with, and not to extend beyond the scope of Licensee’s rights and obligations under, and the terms and conditions of, this Agreement, which written sublicense agreement shall require the Sublicensee to agree to be bound by and comply with
provisions that are consistent with the provisions of this Agreement. Licensee shall remain responsible for compliance by any Sublicensee or CMO receiving any rights hereunder with all terms and conditions of this Agreement relevant to such
Sublicensee or CMO. 
 ARTICLE III 
 Payments 
 3.1 Milestones. As consideration for the rights and licenses granted to
Licensee upon the achievement of [**] of the Agenus Product (including as part of a Combination Product) of [**] U.S. dollars ($[**] USD) (as measured on an Agreement year basis until the [**] anniversary of the Effective Date, and as measured
during any [**] period thereafter), Licensee shall pay Agenus [**] U.S. dollars ($[**] USD) within thirty days (30) of such achievement. Licensee shall promptly give Agenus notice of the occurrence of such milestone. 

[**] made in any currency other than United States dollars shall be converted to United States dollars for the purpose of assessing achievement of this
milestone. Such conversion shall be done in accordance with the following formula:
 A/B = United States dollar sales amount for
each month, where 
 A = foreign currency [**] in the applicable month; and 

B = foreign exchange conversion rate, expressed in local currency per United States dollar (using as the applicable foreign exchange
conversion rate, the rate established by the Central Bank of the Russia Federation, or any other mutually agreed-upon source, for the last five (5) business days of each month). 
 3.2 Agenus Product Supply Pricing and Payment Terms. 
 3.2.1
Pricing. For each patient batch of Agenus Product that may be supplied by Agenus pursuant to Section 12.3, Licensee shall purchase such Agenus Product at a transfer price (the “Price”) of $[**] USD per patient batch, subject to
the remaining provisions of this Agreement. For Agenus Product so supplied by Agenus pursuant to Section 12.3 and to be used by Licensee for use in clinical trials under the Development Plan and for which Licensee

  
 [**] = Portions of this
exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

 
makes [**] or receives any other form of [**], Agenus shall supply such Agenus Product at [**] (i.e., at a Price of $[**] USD per [**]); provided, however, that is without in any way limiting
Agenus’ other rights under this Agreement, in the event that Licensee has not met the [**] (as defined in Section 12.2(a)) by the [**] of the Effective Date and Agenus agrees to [**] the relevant milestone deadlines pursuant to the
provisions of this Agreement, then Licensee shall pay Agenus a Price of $[**] USD per patient batch for such Agenus Product supplied by Agenus pursuant to Section 12.3. The Price does not include, and Licensee shall be solely responsible for:
(i) costs of transporting Biomaterials to Agenus’ facility in Lexington, MA, USA, including any additional licenses Agenus would need to obtain to facilitate such activities, (ii) costs of shipping Agenus Product to the Territory (CIP
Moscow, customs border or such other country border within the Territory as may be agreed to between the Parties), including any additional licenses Agenus would need to obtain to facilitate such activities, and (iii) all other costs and
expenses related to the supply of the Agenus Product by Agenus, such as customs fees, VAT, etc. For the avoidance of doubt and notwithstanding any other provision of this Agreement, in the event that Licensee sells Agenus Product to a Third Party
for use in [**] under the Development Plan, Licensee shall compensate Agenus the applicable $[**] USD or $[**] USD Price for such Agenus Product supplied by Agenus pursuant to Section 12.3. In addition to the applicable Price set forth above,
in the event that Licensee sells any Agenus Product supplied by Agenus pursuant to Section 12.3 at a Gross Sales price above $[**] USD per patient batch, then in addition to the Price for such Agenus Product, Licensee shall also pay Agenus a
royalty of [**]% on the difference in Net Sales for such Agenus Product. 
 3.2.2 Payment Terms. Agenus shall invoice
Licensee for each Agenus Product sold for which payment is owing pursuant to this Section 3.2. Invoices may be sent by Agenus via email or in hard copy, such as with the Agenus Product shipment. Licensee shall pay Agenus the Price for each
Agenus Product and any royalty that may be owing under Section 3.2.1 above within the earlier of (i) five (5) Business Days of the receipt of payment to Licensee from the purchaser or (ii) sixty (60) days of delivery of
Agenus Product to the Russian custom’s border (or other applicable country within the Territory’s customs border). Unless otherwise elected by Agenus, Licensee shall make all payments required under this Agreement in United Stated Dollars
by wire transfer to an account specified by Agenus. Licensee shall be responsible for the banking charges associated with any wire transfers under this Agreement. 
 3.3 Royalties. Subject to other terms of this Agreement, and as consideration for the rights and licenses granted to Licensee hereunder, Licensee shall pay royalties to Agenus on Net Sales of
Agenus Product not supplied by Agenus pursuant to Section 12.3 as follows: 
  

	 	(i)	Licensee will pay to Agenus a royalty of [**] percent ([**]%) of Net Sales of each Agenus Product in the Territory. 

  
 [**] = Portions of this
exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

	 	(ii)	In the event of Regulatory Approval of the Combination Product in a given Territory, Licensee would pay to Agenus a royalty of [**] percent ([**]%) of Net Sales of such
Combination Product in such Territory. For the avoidance of doubt, Net Sales of Agenus Product made prior to Regulatory Approval of the Combination Product would be subject to the royalty provisions of Section 3.3(i) above.

 3.4 Royalty Term. Licensee will make royalty payments on a country-by-country basis during the Term, as may be extended
pursuant to Section 10.2. 
 3.5 Royalty Payments, Reports and Records 

 

	 	3.5.1	Commercial Introduction. Licensee shall promptly give Agenus notice of the occurrence of the First Commercial Sale of the Agenus Product and the First Commercial
Sale of the Combination Product, if applicable, in each country within the Territory hereunder. In no event shall the First Commercial Sale of any Agenus Product occur prior to January 31, 2012 unless otherwise agreed in writing between the
Parties. 

  

	 	3.5.2	Royalty Payments. 

 (a)
Payments: Deduction of Taxes. A royalty report and payment under this Agreement on Net Sales of the Agenus Product will be due and payable from Licensee to Agenus within forty-five (45) days of the last calendar day of each month.
Licensee will remit any such payment due to Agenus under this Agreement by wire or check payable to Agenus. Licensee shall make applicable withholding payments due on behalf of Agenus and shall promptly provide Agenus with written documentation of
any such taxes withheld and paid by Licensee or its Sublicensees for the benefit of Agenus. Notwithstanding the foregoing, if Agenus is entitled under any applicable tax treaty to a reduction of the rate of, or the elimination of, applicable
withholding tax, it may deliver to Licensee or the appropriate governmental authority (with the assistance of Licensee to the extent that this is reasonably required and is expressly requested in writing) the prescribed forms necessary to reduce the
applicable rate of withholding tax or to relieve Licensee of its obligation to withhold tax, and Licensee shall apply the reduced rate of withholding tax, or dispense with withholding tax, as the case may be. If, in accordance with the foregoing,
Licensee withholds any amount, it shall pay to Agenus the balance when due, make timely payment to the proper taxing authority of the withheld amount, and send to Agenus proof of such payment within thirty (30) days following that payment. In
addition to, and notwithstanding any other provision of this Agreement, in the event that Licensee grants a sublicense or assigns its rights and obligations hereunder, and as a result of such sublicense or assignment, a deduction or withholding on
any payment to Agenus under this Agreement is required by any applicable 

  
 [**] = Portions of this
exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

 
law that would not have been required absent such sublicense or assignment, then Licensee (including its successors, transferees, and assigns) will pay (or authorize payment) to Agenus such
additional amount as is necessary to ensure that the net amount actually received by Agenus (free and clear of any tax/withholding, including any tax/withholding imposed on or with respect to the additional amount, whether assessed against Licensee
or Agenus) will equal the full amount Agenus would have received had no such deduction or withholding been required. 
 (b)
Foreign Currency Conversion. For sales of any Licensed Product that occur in a currency other than United States dollars (“Foreign Currency Sales”), the monthly royalty payment will be calculated as follows: 

(A/B) X C = United States dollars royalty payment on Foreign Currency Sales, where 

A = foreign currency Net Sales per month; B = foreign exchange conversion rate, expressed in local currency per United States dollar
(using as the applicable foreign exchange conversion rate, the rate established by the Central Bank of the Russia Federation, or any other mutually agreed-upon source, on the day of payment); and 

C = the royalty rate applicable to such Net Sales under Section 3.3. 

3.5.3 Royalty Reports. Licensee shall render to Agenus, together with the royalty payment due under Section 3.5.2 for a given
calendar month, within [**] days of the end of such month, a written account for such calendar month showing (a) total Gross Sales and Net Sales for the Agenus Product and the Combination Product in the Territory, separately, and (b) a
calculation of the royalties payable under Section 3.3, or 3.2.2 if applicable, for the Agenus Product (including, in the case of foreign currency sales, the total foreign currency Net Sales during such calendar month, the applicable foreign
exchange conversion rate(s) and the total United States dollar royalty payment amount). 
 3.6 Delinquent Payments. Any delinquent
payment amounts under this Agreement shall bear interest at a rate equal to [**] percent ([**]%) per month ([**] percent ([**]%) per [**]) or, if lower, at the maximum rate allowed by applicable law. Agenus reserves the right to withhold delivery of
Agenus Product during any period in which Licensee has any amounts outstanding and past due. Such withholding of delivery will not constitute a breach of Agenus’ obligations. 
 3.7 Licensee’s Recordkeeping and Inspection. Licensee shall keep records of all sales of Agenus Product and Combination Product in sufficient detail to permit Agenus to confirm the accuracy of
payments owing and made hereunder, for a period of at least [**] years from the 

  
 [**] = Portions of this
exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

 
date such payments would be owing hereunder. At the request of Agenus no more frequently than once per year, upon at least ten (10) business days’ prior written notice to Licensee from
Agenus, and at the expense of Agenus (except as otherwise provided below), Licensee shall permit a U.S. nationally recognized, independent certified public accountant selected by Agenus and reasonably acceptable to Licensee to inspect, during
regular business hours, any such Licensee records solely to the extent necessary to verify such calculations, provided that such accountant in advance has entered into a confidentiality agreement with Licensee (substantially similar to the
confidentiality provisions of this Agreement) limiting the disclosure of such information to authorized representatives of the Parties. Results of any such inspection shall be made available to both Parties. If such inspection reveals a deficiency
in the calculation of payments owed or owing resulting in an underpayment to Agenus, Licensee shall promptly pay the difference owing, and in the event that the deficiency in the calculation of payments owed or owing results in an underpayment to
Agenus by five percent (5%) or more, Licensee shall promptly pay all reasonable costs and expenses of such inspection. 
 3.8
Acknowledgement. The Parties acknowledge and agree that (i) the compensation terms set forth in this Agreement were agreed to after careful evaluation of various alternatives to reasonably compensate Agenus for its substantial investment
over time in developing the Agenus Product, Licensed Patent Rights and Licensed Know-how, including without limitation potential up-front payments, refunds for past investments by Agenus, milestone payments, royalties, and maintenance fees, and
(ii) the current payment terms as set forth herein where agreed to by Agenus and Licensee each, for the convenience of the Parties, including to enable Licensee to defer payment obligations. 

ARTICLE IV 

Joint Steering Committee and Specific Responsibilities of the Parties 
 4.1 Joint Steering Committee. 
 (a) Within thirty (30) days after the
Effective Date, Agenus and Licensee will establish a joint steering committee (the “JSC”) to oversee the activities to be undertaken pursuant to this Agreement. The JSC will facilitate communication between the Parties and provide a
forum to review any matters relating to manufacturing technology transfer, supply, the Commercialization Plan and the Development Plan. The JSC shall consist of an equal number of individuals appointed by each Party (up to three (3) per Party),
or such other number of representatives the Parties may mutually agree upon, and may also include additional representatives from the Parties, as mutually agreed, on an ad-hoc basis. The JSC shall be co-chaired by one appointee of each of Agenus and
Licensee. The co-chairs will coordinate agendas and minute-taking for meetings of the JSC. Each Party may replace its JSC representatives at any time upon written notice to the other Party provided that, the Party intending to change its
representative(s) will first notify the other Party and will take the other 

  
 [**] = Portions of this
exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

 
Party’s reasonable objection to any such replacement into consideration. Meetings of the JSC shall be effective only if at least one representative of each Party is present and
participating. The JSC may establish certain ad hoc sub-committees which consider certain matters, including without limitation, one or more sub-committees (consisting of at least one (1) individual from each Party). Each Party shall be
responsible for its own expenses for participating in the JSC. 
 (b) The JSC shall meet (in person, or by teleconference or
videoconference as agreed by the Parties) at least once quarterly (or more frequently as the Parties mutually agree is appropriate, or on such dates and at such times as the Parties shall agree). The JSC (itself or through one or more
sub-committees) will, among other things: (i) develop and oversee the commercialization activities relating to the Agenus Product in the Licensed Indication in the Territory, in accordance with the commercialization plan and budget (the
“Commercialization Plan”), and (ii) develop and oversee the development activities relating to the Combination Product in the Development Indication, in accordance with the 3 year development and regulatory strategy,
implementation plan and budget for the Combination Product in the Development Indication in the Territory (the “Development Plan”), as may be amended from time to time by the JSC, (iii) discuss and review the conceptual design
of Licensee’s or CMO’s manufacturing facility for Agenus Product and discuss and review validation plans for manufacturing, QC testing and facilities; and (iv) address such other matters as may be agreed to between the Parties,
including open matters that may exist at the level of the sub-committees. The initial Development Plan and Commercialization Plan shall be consistent with the provisions of Exhibit E-1 and E-2 respectively and shall be agreed to between the Parties
within forty-five (45) days of the Effective Date, and may thereafter be amended from time to time by the JSC. 
 (c)
Decisions of the JSC will be made by unanimous consent of the co-chairs. In the event that the co-chairs of the JSC cannot come to consensus within thirty (30) days with respect to any matter over which the JSC has authority and responsibility,
the JSC shall submit the matter to dispute resolution in accordance with Section 13.4. 
 (d) The JSC shall continue to
exist until the first to occur of: (a) the Parties mutually agreeing to disband the committee; or (b) Agenus providing to Licensee written notice of its intention to disband and no longer participate in the JSC. 

(e) Should the JSC disband per subsection (d), above, and not as part of the termination of this Agreement, the Parties agree to each
nominate a single point of contact within their respective companies, to facilitate the continuation of the activities and projects contemplated by this Agreement. 
 4.2 Certain Responsibilities of the Parties. The Parties acknowledge and agree that, subject to the provisions of this Agreement: (i) Licensee shall be primarily responsible for conducting the
development activities under the Development Plan and all commercialization 

  
 [**] = Portions of this
exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

 
activities under the Commercialization Plan, unless otherwise expressly set forth in this Agreement, at its sole cost and expense, (ii) Agenus shall reasonably cooperate with Licensee in
connection therewith by providing reasonable access to (a) Licensed Know-How necessary to conduct the Development Plan and Commercialization Plan activities, and (b) personnel necessary to carry out the Commercialization Plan or
Development Plan, at Agenus’ sole cost and expense up to a maximum of $[**] USD during the Term (including FTEs at an annual FTE rate of $[**] USD), and Licensee shall reimburse Agenus all costs and expenses of Agenus, in excess of such $[**]
cap, and in each case provided that such cooperation does not unreasonably interfere with the business operations of Agenus, (iii) Agenus shall provide available and approved tumor procurement/shipping kits for the Biomaterials and the Agenus
Product during the Supply Period; and (iv) Licensee shall provide Licensee Product for use in the Development Plan activities during the Term at its sole cost and expense. In addition, and for the avoidance of doubt, Licensee shall have the
following responsibilities: (a) use its best commercially reasonable efforts to commercialize the Agenus Product in the Territory in accordance with the provisions of the Agreement, the Commercialization Plan, and all applicable laws;
(b) conduct a limited physician post marketing (observation or “registry”) study (PhIV) in the Licensed Indication during the initial Term; (c) conduct all marketing and sales activities for the Agenus Product in the Territory in
the Licensed Indication (and Development Indication, if applicable) in accordance with a Commercialization Plan; (d) manage all tumor procurement and logistical activities; (e) manage all regulatory and pharmacovigilance activities for the
Agenus Product in the Territory in the Licensed Indication and the Combination Product in the Development Indication in accordance with Article VI; (f) expeditiously obtain and maintain Biomaterial export and Agenus Product import licenses
during the Supply Period, if applicable; (g) act as importer for tumor procurement/shipping kits during the Supply Period, if applicable; and (h) manufacture all Agenus Product for the Territory and Approved Indication and Development
Indication in accordance with the Technology Transfer Plan and applicable laws, rules and regulations, other than any Agenus Product that may be supplied by Agenus pursuant to Section 12.3. Licensee acknowledges and agrees to the following
obligations: (i) Licensee shall conduct all activities in the Territory with respect to the Agenus Product and Combination Product and its activities hereunder in accordance with this Agreement, the Specifications, and all applicable laws,
rules, regulations and guidelines; and (ii) Licensee shall obtain and maintain all permits, licenses, filings, certifications or other authorizations required by Regulatory Authorities for the performance of its rights and obligations under
this Agreement. 
 ARTICLE V 
 Due Diligence 
 5.1 Maintenance of License. In order to maintain the licenses
granted pursuant to Section 2.1, Licensee shall use its best commercially reasonable efforts at its sole cost and expense to (i) complete the Manufacturing Diligence Milestones (as defined in Section 12.2) by the

  
 [**] = Portions of this
exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

 
Manufacturing Milestone Deadlines (as defined in Section 12.2 and subject to Section 12.2(b)) and (ii) market and sell the Agenus Product in the Licensed Indication in the
Territory and conduct the Development Plan activities, in each case in accordance with applicable laws, rules and regulations, and the provisions of this Agreement, including without limitation, meeting the following commercial milestones by the
applicable milestone dates below (each a “Commercial Milestone Deadline”): 
  

			
	 MILESTONE
	  	 MILESTONE DATE

	$[**] USD in [**] Gross Sales	  	By [**], provided that in the event that [**] the [**], then within first [**] months of the [**] date,
		
	$[**] USD in [**] Gross Sales	  	between [**] and [**], provided that in the event that [**] the [**], then between the [**] and [**] [**] of the [**] date
		
	$[**] USD in [**] Gross Sales	  	between [**] and [**], provided that in the event that [**] the [**], then between the [**] and the [**] [**] of the [**] date

 In the event that any of the milestones above are not met by the respective milestone date, the Parties
shall meet to discuss the reasons for failure. In the event that Licensee demonstrates to Agenus’ satisfaction that it used its best commercially reasonable efforts to meet such milestone, the Parties shall agree upon an appropriate extension
for achievement of such milestone and Agenus shall not have the right to terminate the Agreement. In addition and notwithstanding the above, in the event that Licensee fails to demonstrate to Agenus’ satisfaction that it used its best
commercially reasonable efforts to meet any of the above commercial milestones by the milestone dates (or any extension allowed for above), Agenus shall have a right to terminate the Agreement upon 60 days written notice to Licensee. Upon receipt of
any termination notice under this Agreement, Licensee shall immediately cease taking new product orders with respect to Agenus Product and Combination Product (if applicable) unless otherwise agreed in writing between the Parties, and shall cause
its Sublicensees and distributors to do the same. 
 Gross Sales made in any currency other than United States dollars shall be converted to
United States dollars for the purpose of assessing achievement of this milestone. Such conversion shall be done in accordance with the following formula:
 A/B = United States dollar sales amount for each month, where 
 A = foreign
currency Gross Sales in the applicable month; and 

  
 [**] = Portions of this
exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

 B = foreign exchange conversion rate, expressed in local currency per United States dollar
(using as the applicable foreign exchange conversion rate, the rate established by the Central Bank of the Russia Federation, or any other mutually agreed-upon source, for the last five (5) business days of each month). 

ARTICLE VI 

Regulatory Matters 
 6.1
Regulatory Filings  
 (a) Agenus Product. 

(i) Agenus will maintain and transfer to Licensee the registration certificate for Regulatory Approval of the Agenus Product for the
Licensed Indication in Russia (the “Registration Certificate”) upon the later of (i) Licensee’s achievement of the Production Milestone or (ii) the extension of the initial Registration Certificate (the
“Certificate Transfer Date”); provided that Licensee is in full compliance with the provisions of this Agreement. In furtherance thereof and subject to the foregoing, the Parties shall work together to begin the process of filing
necessary amendments in a timely manner so as to mitigate the chances of a potential lag in the effectiveness of the Registration Certificate. Upon transfer of the Registration Certificate to Licensee hereunder, Licensee shall be responsible for the
maintenance thereof in accordance with the remaining provisions of this Section 6.1 at its sole cost and expense. 
 (ii)
Except as expressly set forth above and unless otherwise agreed in writing between the Parties, Licensee shall be responsible for preparing and filing all Regulatory Materials, including without limitation furnishing timely notice of all side
effects, drug interactions and other adverse effects identified or suspected with respect to the Agenus Product, and seeking all Regulatory Approvals for the Licensed Indication in the Territory in the name of Licensee, and for all communications
and other dealings with the Regulatory Authorities relating to the Agenus Product in the Territory. Notwithstanding the foregoing or any other provision of this Agreement, Agenus shall have the right to review and pre-approve and/or propose
modifications of, all such materials, approvals and communications, as well as all marketing and/or education materials collectively referred to herein as “Pre-Certificate Transfer Date Regulatory Materials”) relating to the Agenus Product
prior to the Certificate Transfer Date. NewVac shall provide all such Pre-Certificate Transfer Date Regulatory Materials to Agenus in both the Russian and English languages in a timely manner, and Agenus will provide to NewVac a response (in
English) approving or requesting modifications to such Pre-Certificate Transfer Date Regulatory Materials within 5 business days from receipt thereof. 

  
 [**] = Portions of this
exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

 (iii) Upon the expiration or termination of this Agreement, Licensee shall promptly take
all actions necessary to make Agenus the legal and beneficial owner of all Regulatory Approvals and Regulatory Materials for the Agenus Product in the Territory. In the event that any such Regulatory Approvals and/or Regulatory Materials are not
transferable to Agenus, then Licensee shall use its best efforts, at its own expense, to assist Agenus in obtaining Regulatory Approvals and/or Regulatory Materials substantially similar to the non-transferable Regulatory Approvals and/or Regulatory
Materials. Without in any way limiting the foregoing, upon the expiration or termination of the Agreement, the Registration Certificate would be re-transferred to Agenus, and Licensee would take all legal actions necessary to facilitate such
transfer or reissuance. 
 (iv) Combination Product. Unless otherwise agreed in writing between the Parties, Licensee
shall be responsible for preparing and filing all Regulatory Materials, including without limitation furnishing timely notice of all side effects, drug interactions and other adverse effects identified or suspected with respect to the Combination
Product, and seeking all Regulatory Approvals in the Development Indication in the Territory. All Regulatory Materials for the Combination Product in the Territory shall be filed in the name of Licensee, and Licensee shall be responsible for all
communications and other dealings with the Regulatory Authorities relating to the Combination Product in the Territory. Notwithstanding the foregoing or any other provision of this Agreement, Agenus shall have the right to review and pre-approve
and/or propose modifications of, all Pre-Certificate Transfer Date Regulatory Materials relating to the Combination Product prior to the Certificate Transfer Date. NewVac shall provide all such Pre-Certificate Transfer Date Regulatory Materials to
Agenus in both the Russian and English languages in a timely manner, and Agenus will provide to NewVac a response (in English) approving or requesting modifications to such Pre-Certificate Transfer Date Regulatory Materials within a commercially
reasonable time from receipt thereof. Licensee shall be the legal and beneficial owner of all Regulatory Approvals, to the extent applicable during the Term, and Regulatory Materials for the Combination Product in the Territory or in the event any
such Regulatory Approvals and/or Regulatory Materials may not be owned by Licensee, they shall be held for the benefit of Licensee and shall be transferable as directed by Licensee, subject to Section 13.2. 

6.2 Dealings with Regulatory Authorities. In addition and notwithstanding the foregoing, each Party shall promptly notify the other Party of all
Regulatory Materials that it submits pursuant to this Agreement, and, at the other Party’s request, shall promptly provide the other Party with a copy of such Regulatory Materials. Each Party will provide the other Party with reasonable advance
notice of any scheduled meeting with any Regulatory Authority in the Territory relating to the Agenus Product or Combination Product in the Licensed Indication or Development Indication (as applicable), and the other Party shall have the right to
participate 

  
 [**] = Portions of this
exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

 
in any such meeting, to the extent permitted by law. Each Party shall promptly furnish the other Party with summaries (in English) of all material correspondence or material meetings with any
Regulatory Authority relating to the Agenus Product or Combination Product in the Licensed Indication or Development Indication (as applicable) in the Territory, and each Party shall, at the other Party’s request, promptly furnish the other
Party with copies of such correspondence or copies of minutes of such meetings in English. 
 6.3 Adverse Events. Licensee agrees,
subject to regulatory guidelines and restrictions, to provide Agenus with all safety information developed during the course of its studies in humans on the Agenus Product or Combination Product. On an on-going basis during the Term and for the term
during which Licensee has any safety reporting responsibilities for the Agenus Product or Combination Product, Licensee agrees to provide Agenus with any written information in its possession and Control which likely related to adverse effects in
humans associated with the Agenus Product or Combination Product, and all written information in its possession and Control of a reasonably material nature regarding the amelioration of such adverse events. 

6.4 Product Withdrawals and Recalls. In the event that any Regulatory Authority (a) threatens or initiates any action to remove the Agenus
Product or Combination Product from the market in any country in the Territory or (b) requires Licensee or its Affiliates to distribute a “Dear Doctor” letter or its equivalent regarding use of the Agenus Product or Combination
Product in the Territory, Licensee shall notify Agenus and the JSC of such event within one (1) business day after Licensee becomes aware of the action, threat, or requirement. The JSC shall immediately evaluate the request of such Regulatory
Authority prior to initiating a recall or withdrawal of the Agenus Product or Combination Product in the Territory. If the Parties do not reach an agreement within five (5) business days the final decision as to whether to recall or withdraw
the Agenus Product or Combination Product or take other remedial action in the Territory, such decision will be the responsibility of the party holding the Registration Certificate. Licensee will be responsible, at its sole expense, for conducting
any recalls or taking such other necessary remedial action related to the Agenus Product or Combination Product. Licensee shall maintain complete distribution records by purchaser, and by unique patient code and batch number for all Agenus Product
or Combination Product sold within the Territory in accordance with cGMPs. If either Party becomes aware of information about the Agenus Product or Combination Product indicating that it may not conform to the Specifications for the Agenus Product
(including as part of a Combination Product), or that there are potential adulteration, misbranding and/or other issues regarding safety or effectiveness, it shall promptly so notify the other Party. 

  
 [**] = Portions of this
exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

 ARTICLE VII 
 Representations and Warranties and Obligations of the Parties 
 7.1 General Licensee
Representations. Licensee represents and warrants and agrees as follows as of the Effective Date: 
 (a) Organization,
Standing and Authority. Licensee is a company duly organized, validly existing and in good standing under the laws of Russia. Licensee has all requisite corporate power to own and operate its properties and assets and to carry on its business as
presently being conducted and as proposed to be conducted. Licensee has, and will have on all relevant dates, all requisite legal and corporate power to execute and deliver this Agreement, and to carry out and perform its obligations under the terms
of this Agreement. 
 (b) The execution and delivery of this Agreement and the performance of the transactions contemplated
hereby have been duly authorized by all appropriate Licensee corporate action. The performance by Licensee of any of terms and conditions of this Agreement on its part to be performed does not and will not constitute a breach or violation of any
other agreement or understanding, written or oral, to which it is a party. 
 7.2 General Agenus Representations and Obligations. Agenus
represents and warrants and agrees as follows as of the Effective Date: 
 (a) Organization, Standing and Authority.
Agenus is a corporation duly organized, validly existing and in good standing under the laws of the state of Delaware. Agenus has all requisite corporate power to own and operate its properties and assets and to carry on its business as presently
being conducted and as proposed to be conducted. Agenus has, and will have on all relevant dates, all requisite legal and corporate power to execute and deliver this Agreement. 

(b) The execution and delivery of this Agreement and the performance of the transactions contemplated hereby have been duly authorized by
all appropriate Agenus corporate action. The performance by Agenus of any of the terms and conditions of this Agreement on its part to be performed does not and will not constitute a breach or violation of any other agreement or understanding,
written or oral, to which it is a party. Agenus has the full right and legal capacity to provide in the Territory all rights to the Licensed Know-how and Licensed Patent Rights granted to Licensee hereunder. 

(c) Agenus shall maintain all permits, licenses, filings, certifications or other authorizations existing as of the Effective Date to the
extent required by Regulatory 

  
 [**] = Portions of this
exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

 
Authorities for the performance of its rights and obligations under this Agreement. In the event that Licensee seeks Regulatory Approval(s) for territories within the Territory other than the
Russian Federation during the Supply Period, if applicable and subject to Supply Opt Out, Agenus shall reasonably consider any request of Licensee to obtain any additional permits licenses, filings, certifications or other authorizations required by
Regulatory Authorities for Agenus to supply in such territories within the Territory, but shall not be obligated to do so. 
 7.3 Licensee
Performance Representations. Licensee, represents, warrants, and covenants and agrees to Agenus as follows: 
 (a) the
rights conferred hereunder are of significant importance and value to the business prospects of Licensee; 
 (b) Licensee shall
conduct all activities in the Territory with respect to the Agenus Product and Combination Product and its activities hereunder in accordance with this Agreement, the Specifications, and all applicable laws, rules, regulations and guidelines;

 (c) Licensee shall obtain and maintain all permits, licenses, filings, certifications or other authorizations required by
Regulatory Authorities for the performance of its rights and obligations under this Agreement. 
 7.4 U.S. Foreign Corrupt Practices Act
Compliance. 
 (a) Licensee acknowledges that it understands that Agenus is an issuer of securities in the United States and
is subject to the provisions of the U. S. Foreign Corrupt Practices Act, 15 U.S.C. §§ 78m, 78dd-1 through 78dd-3 (“FCPA”). This law prohibits making, promising or offering to make corrupt payments to foreign officials,
political parties or candidates, or making payments to other persons who will offer or make payments to any of the aforementioned parties in order to obtain business, retain business or gain an improper advantage. Licensee represents and warrants
and confirms to Agenus that it is familiar with and understands the FCPA. 
 (b) Licensee is obligated to ensure that throughout
the Term, neither Licensee, nor any person performing activities on behalf of Licensee will engage in any activity that could cause a violation of any provision of the FCPA by Agenus. Licensee represents and warrants and confirms that it has not
made, promised to make, or arranged for any third party to make any payments or gifts to foreign officials in connection with Agenus Product, Combination Product, the practice of any rights or licensed granted under this Agreement, or any activities
contemplated by this Agreement. Further, Licensee represents and warrants and confirms to Agenus that it has not violated any anti-corruption law, including any law applicable within the Territory, and further that Licensee is not involved in,

  
 [**] = Portions of this
exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

 
or the subject of, any investigation involving bribery, corruption or improper payments to foreign government officials, as defined in the FCPA. Licensee agrees to update these foregoing
statements on a periodic basis as required by Agenus in a format prescribed by Agenus. 
 (c) Licensee agrees to notify Agenus
immediately in writing if Licensee or any person who is performing activities on behalf of Licensee is suspected of violating any anti-corruption law or becomes involved in, or a subject of, an investigation or law enforcement inquiry into possible
improper payments to foreign officials or possible violations of anti-corruption laws. Licensee further agrees to provide such notification if Licensee or any person performing activities hereunder on behalf of Licensee becomes involved in any
action, suit, claim, investigation or proceeding that is pending, or to the knowledge of Licensee threatened, relating to a potential violation of any anti-corruption laws, including the FCPA. 

(d) It is agreed between Licensee and Agenus that this Section is deemed by the Parties to be a material provision of this Agreement.

 ARTICLE VIII 
 Indemnification and Liability 
 8.1 Indemnification. 

8.1.1 Indemnification by Licensee. During the Term and thereafter, Licensee shall indemnify and hold Agenus, its Affiliates and their respective
officers, directors, employees, consultants and agents (each, an “Agenus Indemnitee”) harmless against any liability, damages or loss from any Third Party claims, demands, suits, or other proceedings (each a
“Claim”) arising out of, based on or caused by Licensee’s or its Sublicensees’, distributors’ or CMOs’ activities with respect to the Agenus Product or Combination Product or the practice of the licenses granted
hereunder, or otherwise resulting from any activities undertaken by or on behalf of Licensee, its Sublicensees, distributors or CMOS, except to the extent that such Claim is due to product liability arising from Agenus’ negligence or willful
misconduct. 
 8.1.2 Indemnification by Agenus. During the term of this Agreement and thereafter, Agenus will defend, indemnify and hold
harmless Licensee, its Affiliates and their respective officers, directors, employees, consultants and agents (each, a “Licensee Indemnitee”) against any and all third Party Claims arising out of, based on or caused by product
liability issues arising from Agenus’ negligence or the willful misconduct of Agenus. 
 8.1.3 Indemnification Procedures. Any
Agenus Indemnitee or Licensee Indemnitee (each, an “Indemnitee”) shall promptly notify the other Party (the “Indemnitor”) of any loss, claim, damage, liability, or other action in respect of which the Indemnitee intends to
claim such 

  
 [**] = Portions of this
exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

 
indemnification, setting forth the nature of the claim and the basis for indemnification hereunder, and the Indemnitor shall assume the defense thereof with counsel of its choice, subject to such
counsel being reasonably acceptable to the other Party; provided, however, that the Indemnitee shall have the right to retain its own counsel, with the reasonable fees and expenses to be paid by the Indemnitor, only if representation of the
Indemnitee by the counsel retained by the Indemnitor would be inappropriate due to actual or reasonably likely conflicts of interest between such Indemnitee and any party represented by such counsel in such proceedings. The Indemnitee shall
cooperate fully with the Indemnitor in such defense and will permit the Indemnitor to conduct and control such defense and the disposition of such claim, suit, or action (including all decisions relative to litigation, appeal and settlement). The
Indemnitor shall have no liability hereunder for amounts paid in settlement of any loss, claim, damage, liability or action if such settlement is effected by the Indemnitee without the consent of the Indemnitor. The failure to deliver notice to the
Indemnitor promptly after the commencement of any such action, to the extent prejudicial to its ability to defend such action, shall relieve the Indemnitor of any liability to the Indemnitee under this Agreement. The Indemnifying Party agrees not to
enter into any settlement which would have a material adverse effect on the other Party without prior written consent of the other Party, which consent shall not be unreasonably withheld or delayed. 

8.2 LIMITATION OF LIABILITY. EXCEPT A) WITH RESPECT TO LIABILITY RELATING TO THIRD PARTY CLAIMS UNDER SECTIONS 8.1; B) LIABILITY FOR BREACH OF
ARTICLE IX; AND C) CLAIMS FOR MISUSE, MISAPPROPRIATION OR INFRINGEMENT OF INTELLECTUAL PROPERTY, IT IS AGREED BY THE PARTIES THAT NEITHER PARTY NOR ITS AFFILIATES SHALL BE LIABLE TO THE OTHER PARTY OR ITS AFFILIATES FOR ANY SPECIAL, CONSEQUENTIAL,
INDIRECT, EXEMPLARY OR INCIDENTAL DAMAGES (INCLUDING LOST OR ANTICIPATED REVENUES (OTHER THAN REVENUES COMPRISING ROYALTIES OR OTHER PAYMENTS TO BE EARNED AND PAID TO A PARTY BY THE OTHER PARTY UNDER THIS AGREEMENT) OR PROFITS RELATING TO THE SAME),
ARISING FROM ANY CLAIM RELATING TO THIS AGREEMENT, WHETHER SUCH CLAIM IS BASED ON CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE, EVEN IF AN AUTHORIZED REPRESENTATIVE OF SUCH PARTY IS ADVISED OF THE POSSIBILITY OR LIKELIHOOD OF SAME. 

  
 [**] = Portions of this
exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

 ARTICLE IX 
 Confidentiality 
 9.1 “Confidential Information” shall mean any
proprietary and valuable technical, scientific or business information, which the Disclosing Party (as defined below) has taken reasonable measures to protect, furnished by or on behalf of one Party or its Affiliates (the “Disclosing
Party”) to the other Party or its Affiliates (the “Receiving Party”) in connection with this Agreement or the activities contemplated hereunder, regardless of whether such information is specifically designated as confidential and
regardless of whether such information is in oral, written, electronic or other form. Notwithstanding the foregoing or any other provision of this Article IX, the Developments shall be considered the Confidential Information of both Parties, and the
terms of this Agreement shall be considered Confidential Information of both Parties, in each case subject to the provisions of this Article IX and Section 13.6. Confidential Information shall not include information that: (a) is in the
public domain or thereafter becomes available to the public through no act of the Receiving Party; or (b) was independently known to the Receiving Party prior to receipt thereof or was discovered independently outside the scope of this
Agreement by an employee of the Receiving Party who had no access to the information supplied by or on behalf of the Disclosing Party; or (c) was made available to the Receiving Party as a matter of lawful right by a Third Party who had no
obligations of confidentiality to the Disclosing Party. 
 9.2 Obligations. The Receiving Party agrees that it shall not, without the
prior written consent of the Disclosing Party, directly or indirectly: (a) make any use of any portion of the Confidential Information of the Disclosing Party for purposes other than those set forth in this Agreement; or (b) disclose or
transfer any portion of the Confidential Information to any person, except that the Receiving Party may disclose or permit the disclosure of Confidential Information to its Affiliates and sublicensees and subcontractors and partners and its and
their respective directors, officers, employees, consultants, and advisors, and potential collaborative partners, and investors and potential investors in connection with a general financing transaction who are under obligations no less stringent
than those included herein (contractual or otherwise) to maintain the confidential nature of such Confidential Information and who need to know such Confidential Information for the purposes set forth in this Agreement or for other legitimate
business purposes. Notwithstanding the above, the Receiving Party may disclose Confidential Information of the Disclosing Party when required by applicable laws or government rules or regulations (including without limitation, applicable securities
regulations), provided that, to the extent reasonably possible, the Receiving Party provides reasonable prior written notice of such disclosure to the Disclosing Party and takes reasonable and lawful efforts to avoid and/or minimize the extent of
disclosure. 

  
 [**] = Portions of this
exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

 9.3 Upon expiration or termination of this Agreement and upon request of the Disclosing Party, all copies of
any Disclosing Party’s Confidential Information shall be returned to the Disclosing Party or destroyed, such destruction being accompanied by an affidavit certifying the destruction, except that each Receiving Party may retain one (1) copy
of the Confidential Information received hereunder, solely for monitoring its obligations under this Agreement. 
 9.4 No option, license, or
conveyance of such rights, express or implied, is granted to the Receiving Party in connection with any Confidential Information disclosed by the Disclosing Party, except for the express licenses granted in Article II or the rights granted in
Article XI. If any such rights are to be granted to the Receiving Party, such grant shall be expressly set forth in a separate written instrument. 
 ARTICLE X 
 Term and Termination 

10.1 Term. This Agreement shall commence as of the Effective Date and, unless sooner terminated or extended as provided in
this Article X, shall expire on the third
(3rd) anniversary of the Effective Date, provided
that in the event that Agenus exercises the Supply Opt Out pursuant to Section 12.3, and Licensee meets the Production Milestone Deadline, then the Agreement shall expire thirty (30) days after the third (3rd) anniversary of the Production Milestone achievement date (the
“Term”). 
 10.2 Term Extension. The Parties acknowledge that the initial Term is intended for the Parties to
(A) assess the feasibility of Licensee establishing successful manufacturing and commercial operations in the Territory, and (B) generate data under the Development Plan to better formulate potential long term development plans of Licensee
for the Combination Product in the Development Indication in the Territory. In addition, the Parties recognize the prior investment of Agenus and the investments being made by both Parties during the initial Term, and mutual desire for a longer term
commitment pending favorable outcomes. Accordingly, the Parties agree as follows: 
 (a) If: (1) (x) both Parties are
in material compliance with this Agreement, and (y) Licensee has met the milestones set forth in Sections 5.1 and 12.2(a) by the respective deadlines, and (2) Licensee elects in writing to continue the manufacturing and commercialization
of the Agenus Product in the Licensed Indication in the Territory, such writing to be received by Agenus by the Production Milestone achievement date, then the Parties shall amend this Agreement to extend the license granted under
Section 2.1(a) of this Agreement for a period ending the later to occur of: (i) ten years from the Effective Date, or (ii) the expiration of the last Valid Claim of the Licensed Patent Rights, subject to the Parties agreement on a
reasonable on-going Commercialization Plan and related sales milestones. 

  
 [**] = Portions of this
exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

 (b) In the event that Licensee used its best commercially reasonable efforts but did not
meet the milestones set forth in Sections 5.1 and 12.2(a) by the respective deadlines, Agenus shall reasonably consider Licensee’s request to amend this Agreement to extend the license granted under Section 2.1(a) of this Agreement
for a period ending the later to occur of: (i) ten years from the Effective Date, or (ii) the expiration of the last Valid Claim of the Licensed Patent Rights, subject to the Parties agreement on a reasonable on-going Commercialization
Plan, related sales milestones and other terms and conditions; provided that Agenus shall not be obligated to enter into any such amendment. 
 (c) In the event the Agreement is not extended beyond the initial Term, upon Agenus’ request, the Parties agree to negotiate in good faith provisions for the continuation of the manufacture by
Licensee of Agenus Product on behalf of Agenus and/or its designees and to establish a supply agreement for Agenus Product to be manufactured in Licensee’s designated facility for Agenus and/or its Affiliates, licensees and partners.

 (d) Upon the recommendation of the JSC (or agreement of both Parties in the event the JSC is disbanded), and provided the
Parties agree to extend the term of the license granted under Section 2.1(a) of this Agreement pursuant to clauses (i) or (ii) above, the Parties agree to negotiate in good faith an extension of the license granted in
Section 2.1(b) of this Agreement and provisions for further development activities for the Combination Product, including an updated Development Plan. 
 10.3 Material Breach. Failure by either Party to comply with any of the material obligations contained in this Agreement shall entitle the other Party to give to the Party in default written notice
specifying the nature of the default and requiring it to cure such default. If such default is not cured within sixty (60) days after the receipt of such notice, the notifying Party shall be entitled, without prejudice to any of its other
rights conferred on it by this Agreement and in addition to any other remedies available to it by law or in equity, to terminate this Agreement effective upon written notice to the other Party. 

10.4 Termination by Agenus. In addition and notwithstanding the foregoing, Agenus shall have the right to terminate the Agreement upon no less
than sixty (60) days written notice: (i) in the event that manufacturing operations are not maintained in accordance with the Specifications, cGMP and Agenus’ operating procedures, (ii) pursuant to Section 5.1,
(iii) pursuant to Section 12.2(b) and (iv) pursuant to Section 13.7. 
 10.5 Termination by Licensee. Licensee may
terminate this Agreement without cause by giving sixty (60) days written notice to Agenus, provided that upon such termination all rights to Licensed Know-how and Licensed Patent Rights shall revert to Agenus. 

  
 [**] = Portions of this
exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

 10.6 Accrued Rights, Post-Termination Obligations, Sublicensees. 

(a) Upon receipt or delivery of any termination notice under this Agreement, Licensee shall immediately cease taking new product orders
with respect to Agenus Product and Combination Product (if applicable) unless otherwise agreed in writing hereunder, and shall cause its Sublicensees and distributors to do the same. Expiration or any termination of this Agreement for any reason
shall be without prejudice to any rights which shall have accrued to the benefit of either Party prior to such expiration or termination. Unless otherwise agreed in writing by Agenus, expiration or termination of this Agreement shall automatically
terminate any sublicense or CMO agreement. 
 (b) In the event of the termination or expiration this Agreement, Licensee shall
immediately cease and shall instruct its Sublicensees, distributors, and CMOs to immediately: (i) cease any use of the Licensed Patent Rights and Licensed Know-how, and, coordinate the transfer or appropriate disposition of any Biomaterials or
Agenus Product in the possession of Licensee and/or its Sublicensees, CMO, distributors or legitimate third parties in cooperation with and as instructed by Agenus, and (ii) decommission any portion of the manufacturing facility in the
Territory dedicated to Agenus Product manufacture or otherwise containing, incorporating, utilizing, or based on the Manufacturing Technology or other Licensed Know-how, and certify to Agenus that the foregoing has been accomplished. Notwithstanding
the foregoing however, in the event that Licensee believes that it will have any product orders in process at the time of expiration or termination, it shall promptly notify Agenus thereof, and, at the election of Agenus, fill such orders prior to
ceasing operations. Should Agenus elect to immediately take over all sales operations, both Parties agree that Licensee shall receive full credit and compensation for any product orders in process made by Licensee in accordance with the provisions
of this Agreement, less] any royalties or other payments owing to Agenus with respect thereto. Immediately after termination or expiration, Licensee shall provide all cooperation and assistance reasonably requested by Agenus to enable Agenus to
assume and/or continue, with as little disruption as reasonably possible, the continued sale and distribution of Agenus Product in the Territory, including, without limitation, (a) as directed by Agenus, terminate all agreements between
Licensee and any Third Parties relating to the distribution or sale of Agenus Product, or assign them to Agenus or a Third Party designated by Agenus, (b) at the direction of Agenus, remove from any literature or other media of Licensee any and
all references to Agenus and the Agenus Product, (c) cease to use any Agenus Trademarks and Tradenames (as defined in Section 11.4(b)) and assign to Agenus all right, title and interest in any such trademarks or tradenames to the extent
necessary, (d) transfer or assign to Agenus all Regulatory Materials, Regulatory Approvals, licenses, permits, authorizations or similar documents for the Agenus Product that Licensee holds as of the time of any such termination,
(e) return to Agenus all Confidential Information of Agenus, (f) pay Agenus any outstanding invoices and royalty amounts, and (h) provide Agenus with a final marketing and distribution report containing data through the effective date
of the termination or expiration of this Agreement, including without limitation, customer account information and market data and intelligence. 

  
 [**] = Portions of this
exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

 ARTICLE XI 
 Intellectual Property 
 11.1 Inventions. 

(a) This Agreement does not affect the ownership of inventions (whether patentable or unpatentable), trade secrets, works of authorship,
and other developments existing as of the Effective Date, and all patents, copyrights, trade secret rights and other intellectual property rights to such inventions, discoveries, trade secrets, works of authorship, and other developments,
(collectively, “Pre-existing Intellectual Property”). Neither Party shall have any rights to any Pre-existing Intellectual Property of the other Party, except as may be otherwise expressly provided in this Agreement. 

(b) The Parties shall jointly own all data and inventions arising from Licensee’s activities under the Commercialization Plan or
Development Plan (“Developments”), and each Party shall fully cooperate with the other Party to vest title therein with both Parties, including executing any necessary documents of assignment. With respect to the Combination
Product, the Parties acknowledge and agree that it is not feasible at this point in time to determine the long term development and commercialization plans for the Combination Product. Accordingly, the Parties acknowledge and agree that each
Party has and shall have the right to license and otherwise exploit the Developments, subject to any freedom to operate restrictions, without any further accounting to the other Party, provided however, that neither Party is receiving hereunder any
rights to the Pre-existing Intellectual Property or any other intellectual property of the other Party, including without limitation, the Licensed Patent Rights and Licensed Know-how of Agenus, in each case except as expressly set forth in the
Agreement.
 11.2 Patent Prosecution Strategy. Subject to the other terms of this Agreement, as mutually agreed by the Parties, one Party
shall assume responsibility (the “Controlling Party”) for the preparation, filing, prosecution, and maintenance of all U.S. and foreign patent applications and patents covering Developments (“Development Patent
Rights”), using patent counsel reasonably acceptable to both Parties, and the non-Controlling Party shall reasonably cooperate with respect thereto. The Controlling Party shall (i) notify the non-controlling Party reasonably prior
to the filing of any Development Patent Rights and permit review of such Development Patent Rights by the non-Controlling Party, (ii) provide the non-Controlling Party promptly with copies of all communications received by the Controlling Party
with respect to Development Patent Rights, (iii) keep the non-Controlling Party reasonably informed of the status of such Development Patent Rights, and (iv) provide the non-Controlling Party notice at least thirty (30) days in
advance of taking or failing to take any action that would affect the scope or validity of any such Development Patent Rights (including but not limited to substantially narrowing or canceling any claim, abandoning any

  
 [**] = Portions of this
exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

 
such Development Patent Rights or not filing or perfecting the filing of any such Development Patent Rights in any country), with prior written notice of such proposed action or inaction so that
the non-Controlling Party has a reasonable opportunity to review and make comments. Unless otherwise agreed, the Parties shall share equally the expenses of such preparation, filing, prosecution, and maintenance. Either Party may assign its rights
to any jointly owned Development Patent Rights to the other Party, who will have the right in its discretion, to assume the prosecution and maintenance thereof at its sole expense and as the sole owner thereof. 

11.3 Third Party Infringement. Either Party promptly shall notify the other Party in writing of any alleged infringement of the Licensed Patent
Rights in the Territory, or the Development Patent Rights and of any available evidence thereof. The Parties shall consult as to a potential litigation strategy or strategies against any alleged infringer. If the Parties commence and prosecute a
suit jointly, Licensee shall pay all associated attorney’s fees and out-of pocket litigation expenses. All monies recovered upon the final judgment or settlement of any such action shall be used (a) first, to reimburse the costs and
expenses (including reasonable attorneys’ fees and costs) of the Parties, (b) second (to the extent that damages are awarded for lost sales or lost profits from the sale of Agenus Product or Combination Product), to Licensee with Agenus
receiving the royalties that would have been payable to Agenus on the sale of such products, and (c) the remainder to be split equally between the Parties. If the Parties do not decide to jointly commence an action within thirty (30) days
of the notice specified above, or otherwise terminate the alleged infringement, Agenus shall have the right, at its expense, to bring suit against the allegedly infringing party. 
 11.4 Trademarks. 
 (a) The terms “Trademark” or
“Tradename” shall include, without limitation, the name or names of any Agenus Product or Combination Product, the design of the packaging of any Agenus Product or Combination Product, and the appearance of dosage forms of any Agenus
Product or Combination Product. 
 (b) Unless otherwise agreed between the Parties in writing, Agenus, at its expense, shall be
responsible for the selection, registration and maintenance of all Trademarks and Tradenames employed in connection with the Agenus Product (the “Agenus Trademarks and Tradenames”). The Agenus Trademarks and Tradenames in the
Territory as of the Effective Date are set forth on Exhibit F. The Agenus Trademarks and Tradenames, and any reputation and goodwill in them, are, and will remain, the exclusive property of Agenus, and Licensee does not have and shall not
have any right to use any Agenus Trademarks and Tradenames other than in connection with the exercise of its rights under the terms and conditions of this Agreement. All use of the Agenus Trademarks and Tradenames shall inure solely to the benefit
of Agenus. 

  
 [**] = Portions of this
exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

 (c) Subject to the foregoing and the remaining provisions of this Agreement, Agenus hereby
grants to Licensee a license to use the Agenus Trademarks and Tradenames in the Territory during the Term solely in connection with the exercise of the licenses granted in Section 2.1, and in conformance with the standards established by
Agenus. Licensee shall not: (i) use any Agenus Trademarks and Tradenames, or any word, symbol, or design confusingly similar to any Agenus Trademarks and Tradenames as part of its corporate or legal name or in connection with any product sold
by Licensee, its Sublicensees or distributors except as set forth herein; or (ii) do or cause to be done any act or thing which would in any way impair the rights of Agenus in and to any Agenus Trademarks and Tradenames. The use of Trademarks
and Tradenames in connection with the sale of Combination Products shall be as agreed to between the Parties. 
 ARTICLE XII

 Manufacture and Supply 
 12.1 Manufacturing Technology Transfer. The Parties shall use commercially reasonable efforts to complete the Manufacturing Technology transfer in accordance with the plan and timelines as set
forth in this Article XII and the technology transfer plan governing the transfer of the Manufacturing Technology between the Parties (the “Technology Transfer Plan”). The initial Technology Transfer Plan is attached to this
Agreement as Exhibit G, and may be updated between the Parties upon mutual written agreement within thirty (30) days of the Effective Date. Agenus will provide reasonable training to Licensee and assist Licensee in the Manufacturing Technology
transfer process in accordance with the Technology Transfer Plan at its sole cost and expense up to $[**] USD (including FTEs at an annual FTE rate of $[**] USD). Licensee shall reimburse Agenus all costs and expenses of Agenus in excess of such
$[**] cap. Due to the unique nature of the manufacturing process for the Agenus Product which was perfected by Agenus over time, it is critical that Licensee maintain the integrity and quality of the manufacturing process. Upon the written request
of Licensee, the Parties shall enter into a quality agreement governing the manufacture of the Agenus Product in the Territory during the Supply Period, which shall contain typical terms and conditions as agreed to between the Parties. In addition,
the Parties shall agree upon appropriate, thorough, and meaningful safeguards for Agenus, including the following (i) Licensee shall guarantee to hire the appropriate amount of qualified Licensee employees in Russia to the reasonable
satisfaction of Agenus to ensure a smooth transition, (ii) Agenus will have the right to pre-approve the manufacturing facility, and (iii) Agenus will have the right (but not the obligation) to have an employee or consultant in the
manufacturing facility overseeing and approving manufacturing operations and release of Agenus Product until the Production Milestone is achieved. 

  
 [**] = Portions of this
exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

 12.2 Licensee Obligations to Establish Manufacturing Capability. 

(a) Licensee shall use its best commercially reasonable efforts at its sole cost and expense to do the following activities, in each case
in accordance with all applicable laws, rules and regulations, and the provisions of the Agreement: (i) manufacture, market and sell the Agenus Product in the Licensed Indication in the Territory in accordance with the Specifications and the
Commercialization Plan, (ii) carrying out the Development Plan, and (iii) establish manufacturing capability in the Territory, including without limitation, meeting the following milestones (each a “Manufacturing Diligence
Milestone”): 
  

			
	 MILESTONE:
	  	 DATE

	Identify [**] for [**]	  	[**] days from Effective Date
		
	[**] of NewVac [**] (Agenus sign off, requires [**] of [**] and [**] of [**])	  	[**] from Effective Date
		
	[**] for [**] to [**] of [**] (“[**] Milestone”)	  	[**] from Effective Date
		
	Obtain [**] for [**] for [**] (“[**] Milestone”)	  	[**] from [**] Milestone
		
	Produce [**] of Agenus Product manufactured in Russia at the manufacturing facility in accordance with the Specifications (“Production Milestone”)	  	[**] after [**]

 (b) In the event that any Manufacturing Diligence Milestone is not met by the respective milestone date
(each date, the applicable “Manufacturing Milestone Deadline”), the Parties shall meet to discuss the reasons for such delay. In the event that Licensee demonstrates to Agenus’ satisfaction that it used its best commercially
reasonable efforts to meet such Manufacturing Milestone Deadline, the Parties shall agree upon an appropriate extension for such Manufacturing Milestone Deadline (a “Milestone Extension”) and Agenus shall not have the right to
terminate the Agreement for such failure, provided that in the event that Agenus elects to exercise the Supply Opt Out pursuant to Section 12.3 below, then in no event shall the Production Milestone Manufacturing Milestone Deadline or any
Milestone Extension thereof (the “Production Milestone Deadline”) extend beyond the third anniversary of the Effective Date unless otherwise agreed by Agenus in its sole discretion. In addition and notwithstanding the above, if
Licensee fails to demonstrate to Agenus’ satisfaction that it used its best 

  
 [**] = Portions of this
exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

 
commercially reasonable efforts to meet the above Manufacturing Diligence Milestones by the Manufacturing Milestone Deadlines or any Milestone Extensions, or for the avoidance of doubt, in the
event that Licensee fails to meet the Production Milestone Deadline, Agenus shall have a right to terminate the Agreement. 

(c) Licensee shall not use any CMO to manufacture or produce the Agenus Product, alone or as part of the Combination Product, without the
prior written consent of Agenus in its sole discretion. 
 12.3 Agenus Product Supply 

(a) Agenus Supply Opt Out. The Parties acknowledge and agree that Agenus shall have the right to opt out of its right and
obligation to supply any Agenus Product under this Agreement (the “Supply Opt Out”) at any time prior to January 31, 2012 upon written notice to Licensee. 

(b) Supply Period Obligations. In the event that Agenus does not exercise the Supply Opt Out pursuant to Section 12.3
(a) above, then from January 31, 2012 (or such sooner period of time as may be elected in writing by Agenus) until the achievement of the Production Milestone (the “Supply Period”), the following provisions shall apply.
During the Supply Period, Licensee agrees to purchase solely from Agenus, and Agenus agrees to use its commercially reasonably efforts to supply Licensee and its Sublicensees with one hundred percent (100%) of their initial requirements of
Agenus Product (subject to the Manufacturing Capacity) for use solely in accordance with the licenses granted pursuant to Section 2.1 of this Agreement. Following the Supply Period, Licensee shall have no further obligation to purchase Agenus
Product from Agenus, and Agenus shall have no further obligation to supply Agenus Product. Subject to the terms and conditions contained in this Agreement, during the Supply Period Licensee shall purchase from Agenus and Agenus shall supply to
Licensee, Agenus Product in the amounts and timelines and pursuant to the terms and conditions set forth in Section 3.2 and on Exhibit H. 
 12.4 Agenus Reservation of Rights. Agenus reserves the right to manufacture (or have manufactured) and supply Agenus Product for itself, Affiliates and/or any Third Parties outside the exclusive
license grants to Licensee hereunder. 

  
 [**] = Portions of this
exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

 ARTICLE XIII 
 Miscellaneous Provisions 
 13.1 No Partnership. Nothing in this Agreement is
intended or shall be deemed to constitute a partnership, distributorship, agency, employer-employee or joint venture relationship between the Parties. No Party shall incur any debts or make any commitments for the other, except to the extent, if at
all, specifically provided herein. 
 13.2 Assignments. Neither Party shall assign any of its right or obligations hereunder or this
Agreement without the prior written consent of the other Party, except that Agenus may do so: (a) to a Third Party as incident to the merger, consolidation, reorganization or acquisition of stock or assets affecting all or substantially all of
the assets of such Party relating to the subject matter of this Agreement (“Acquiring Party”); or (b) to an Affiliate. This Agreement shall be binding upon the successors and permitted assigns of the Parties and the name of a
Party appearing herein shall be deemed to include the names of such Party’s successors and permitted assigns to the extent necessary to carry out the intent of this Agreement. Any permitted assignee shall assume all obligations of its assignor
under this Agreement. No assignment shall relieve any Party of its responsibility for the performance of any obligations that such Party has under this Agreement. Any assignment not in accordance with this Section 13.2 shall be void.

 13.3 Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such acts, as may
be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
 13.4 Dispute Resolutions. Except for
the right of any Party to apply for a temporary restraining order, a preliminary injunction or other preliminary equitable relief in any court or tribunal of appropriate jurisdiction to preserve the status quo or prevent irreparable harm, any
dispute, other than disputes regarding the construction, validity or enforcement of patents, arising between the Parties relating to, arising out of or in any way connected with this Agreement or any term or condition hereof, or the performance by
either Party of its obligations hereunder, whether before or after termination of this Agreement, shall be resolved exclusively as follows: 
 (a) Any Party may trigger this provision by written notice to the other Party that reasonably describes the nature of the dispute; 
 (b) If the dispute cannot be resolved by the Parties through their duly authorized representatives within thirty (30) days of such notice, the Chief Executive Officers of the Parties (or their
respective designees) shall meet in person at a mutually acceptable time and location or by means of telephone or video conference within ten (10) business days of the matter being referred to them. 

  
 [**] = Portions of this
exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

 (c) If the Chief Executive Officers of the Parties (or their respective designees) are
unable to settle any dispute within thirty (30) days, then either Party may initiate mediation upon written notice to the other Party (the “Notice Date”), whereupon both Parties shall engage in a mediation proceeding under the then
current International Institute for Conflict Prevention and Resolution Inc. (“CPR”) Mediation Procedure , except that specific provisions of this Section shall override any inconsistent provisions of the CPR Mediation
Procedures. The mediator will be selected from the CPR Panel of Neutrals. If the Parties cannot agree upon a mediator within 15 business days of the Notice Date, one shall be appointed by the CPR. The Parties shall attempt to resolve
the dispute through mediation until the first of the following to occur: (i) the Parties reach a written settlement, (ii) the mediators notify the Parties in writing that they have reached an impasse, (iii) the Parties agree in
writing that they have reached an impasse, or (iv) the Parties have not reached a settlement within sixty (60) days after the Notice Date. Completion of the requirements of this provision is a condition precedent to proceeding to provision
(d) unless one of the Parties refuses to cooperate in step (c). 
 (d) If the Parties fail to resolve the dispute
through mediation, the Parties shall submit to final and binding arbitration administered by the International Institute for Conflict Prevention and Resolution Inc. pursuant to the International Institute for Conflict Prevention &
Resolution Rules for Non-Administered Arbitration. The Parties agree that the Arbitrator(s) may provide any and all appropriate relief, including injunctive relief. Any such arbitration shall take place in the Commonwealth of
Massachusetts.
 13.5 No Name or Trademark Rights. Except as otherwise provided herein, no right, express or implied, is granted by this
Agreement to use in any manner the names of the Parties or any version or contraction thereof or any other Tradename or Trademark of Agenus or Licensee in connection with the performance of this Agreement. 

13.6 Public Announcements. The Parties have agreed on the pre-cleared content for public disclosure (as described in more detail on Exhibit I
attached hereto) for release by either Party within a reasonable time after the Effective Date. Except for such content, neither Party shall issue any press releases or public disclosure relating to this Agreement without the prior written consent
of the other Party, which consent shall not be unreasonably withheld or delayed, provided, however, that (i) a Party may, without the prior consent of the other Party, issue such press release or public disclosure as may be required by
applicable laws, rules and regulations (including any applicable securities regulations) and (ii) once any press release or other public disclosure is approved for disclosure by the Parties, either Party hereto may make a subsequent public
disclosure of the contents of such approved press release or other public disclosure. Notwithstanding the provisions of Section 13.11 below, for purposes of this Section 13.6, and notices may be sent via email, if to Agenus, to
shalini.sharp@agenusbio.com with a copy to karen.valentine@agenusbio.com, and if to Licensee, to Sergey Bugrov: sb@newvac.ru with a copy to Ron Demuth: rdemuth@torreypinesinv.com. 

  
 [**] = Portions of this
exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

 13.7 Force Majeure. If any default or delay occurs which prevents or materially impairs a
Party’s performance and is due to a cause beyond the Party’s reasonable control, including but not limited to any act of any god, flood, fire, explosion, earthquake, casualty, accident, war, terrorism, revolution, civil commotion, blockade
or embargo, injunction, law, proclamation, order, regulation or governmental demand, the affected Party promptly shall notify the other Party in writing of such cause and shall exercise diligent efforts to resume performance under this Agreement as
soon as possible. Neither Party shall be liable to the other Party for any loss or damage due to such cause. Neither Party may terminate this Agreement because of such default or delay, unless such event continues unabated for a period of [**]
months, in which case the Party disadvantaged by such default or delay may, at its option, terminate this Agreement upon written notice to the other Party. 
 13.8 Entire Agreement of the Parties, Amendments. This Agreement, including the exhibits attached hereto which are incorporated herein, constitutes and contains the entire understanding and
agreement of the Parties and cancels and supersedes any and all prior negotiations, correspondence, understandings and agreements, whether verbal or written, between the Parties respecting the subject matter hereof. No waiver, modification or
amendment or any provision of this Agreement shall be valid or effective unless made in writing and signed by a duly authorized officer of each of the Parties. 
 13.9 Severability. In the event that any of the provisions of this Agreement shall for any reason be held by any court or authority of competent jurisdiction to be invalid, illegal or
unenforceable, such provision or provisions shall be validly reformed to as nearly as possible approximate the intent of the Parties and, if unenforceable, shall be divisible and deleted in such jurisdiction; elsewhere, this Agreement shall not be
affected so long as the Parties are still able to realize the principal benefits bargained for in this Agreement. 
 13.10 Applicable
Law. This Agreement shall be governed by and interpreted in accordance with the laws of the Commonwealth of Massachusetts, USA applicable to agreements made and performed wholly within such state without regard to its principles of conflicts of
laws, provided that questions affecting the construction and effect of any patent shall be determined by the laws of the country in which the patent shall have been granted. The Parties agree that the 1980 United Nations Convention on Contracts for
the International Sale of Goods shall not apply to or affect any term of this Agreement. 
 13.11 Notices and Deliveries. Any notice,
requests, delivery, approval or consent required or permitted to be given under this Agreement shall be in writing and shall be deemed to have been sufficiently given if delivered in person, transmitted by facsimile (with written confirmation to
follow via an internationally recognized courier) or three (3) days after being sent by internationally recognized courier to the Party to whom it is directed at its address shown below or such other address as such Party shall have last given
by written notice to the other Party in accordance with this Section. 

  
 [**] = Portions of this
exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

 If to Agenus, addressed to: 

Agenus Inc. 
 3
Forbes Road 
 Lexington, MA 02421 
 Attn: Chief Financial Officer 
 With a copy to: 

Agenus Inc. 
 3
Forbes Road 
 Lexington, MA 02421 
 Attn: Legal Department 
 If to Licensee, addressed to: 

NewVac LLC 

Rabochaya St. 2-a, Bldg. 1 
 Khimki, Moscow 
 141400, Russia 

Phone: +7 (495) 995-4944 
 Fax: +7 (495) 926 9970 
 Attn: Sergey Bugrov, PhD, CEO 

With a copy to: 
 De Novo Legal PC 
 2244 Faraday Ave. Suite 103 

Carlsbad, CA 92008 
 Attn: Maria Johnson 
 13.12 Governing Language. The Parties acknowledge and agree that the
English language shall govern this Agreement and all communications required or anticipated pursuant to this Agreement. All written materials to be provided by Licensee to Agenus pursuant to this Agreement shall be written in the English language,
and all oral communications between the Parties shall be with fluent English speaking representatives of the Parties. 
 13.13
Counterparts. This Agreement may be executed simultaneously in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Execution and delivery of this
Agreement by 

  
 [**] = Portions of this
exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

 
facsimile or electronic copies bearing the facsimile signatures of the Parties shall constitute a valid and binding execution and delivery of this Agreement by the signing Party, and such
facsimile and/or electronic copies shall constitute original documents. 
 13.14 Compliance with Laws. Licensee and Agenus each shall
comply with all applicable laws in connection with its own performance under this Agreement. Without limiting the generality of the foregoing, Licensee shall be responsible for compliance with all applicable product safety, product testing, product
labeling, package marking, and product advertising laws and regulations, except with respect to efforts performed by Agenus in which case Agenus shall be responsible for its activities as governed by such laws and regulations. 

13.15 Survival. Unless otherwise expressly noted herein, the following provisions shall survive expiration or termination of this Agreement:
Articles III (with respect to payment obligations owing or that have accrued prior to the effective date of expiration or termination, or sales made prior to the effective date of expiration or termination or in accordance with
Section 10.6(b)), Article VIII, and IX, and Sections 6.1(iii), 6.3, 7.3, 7.4, 10.6, 11.1, 11.2, 11.3, 13.4, 13.5, 13.10, 13.12, 13.13, and this Section 13.15. 
 13.16 Construction. Except where the context requires otherwise, the use of any gender is applicable to all genders and the term “including” or “includes” means including,
without limiting the generality of any description preceding such term. The wording of this Agreement shall be deemed to be the wording mutually chosen by the parties and no rule of strict construction shall be applied. All monetary amounts are in
United States dollars unless otherwise explicitly provided. The headings of each Article and Section in this Agreement have been inserted for convenience of reference only and are not intended to limit or expand on the meaning of the language
contained in the particular Article or Section. 
 IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be
signed by their respective corporate officers, duly authorized as of the dates written below. 
  

							
	Agenus	 		 	Licensee
				
	By:	 	 /s/ Garo H. Armen
	 		 	 /s/ Nikolay Savchuk

				
	Name:	 	 Garo H. Armen
	 		 	 Nikolay Savchuk

				
	Title:	 	 Chairman and CEO
	 		 	 Chairman of the Board

				
	Date:	 	 December 16, 2011
	 		 	 December 16, 2011

  
 [**] = Portions of this
exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

 For valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and in
consideration of Agenus executing and delivering this Agreement, Chemrar Group Companies hereby unconditionally guaranties to Agenus, its successors and assigns, full and prompt payment and performance of all of the obligations of Licensee in
connection with this Agreement. This guaranty shall operate as continuing, absolute, and irrevocable. The liability of Chemrar Group Companies hereunder should be primary, and Chemrar Group Companies hereby waives all suretyship defenses.

  

			
	Chemrar Group Companies
		
	By:	 	 /s/ Nikolay Savchuk

		
	Name:	 	 Nikolay Savchuk

		
	Title:	 	 Board Member

		
	Date:	 	 December 16, 2011

  
 [**] = Portions of this
exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission.Amended and Restated Developement and License Agreement

 Exhibit 10.32 
 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* * *” and has been filed separately with the Securities and Exchange Commission pursuant to a
Confidential Treatment Application filed with the Commission 
 AMENDED AND RESTATED 

DEVELOPMENT AND LICENSE AGREEMENT 
 BY AND BETWEEN 
 BIOCRYST PHARMACEUTICALS, INC. 

AND 

MUNDIPHARMA INTERNATIONAL CORPORATION LIMITED 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* *
*” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission 
 TABLE OF CONTENTS 
  

					
	 	  	PAGE	 
		
	 ARTICLE 1 - DEFINITIONS
	  	 	1	  
		
	 ARTICLE 2 - GRANT
	  	 	7	  
		
	 2.1 License Grants
	  	 	7	  
	 2.2 BioCryst Retained Rights
	  	 	7	  
	 2.3 Mundipharma Exclusive Option
	  	 	7	  
	 2.4 BCX-4208
	  	 	8	  
	 2.5 BCX-5235
	  	 	8	  
	 2.6 Mundipharma Research Outside the Field
	  	 	8	  
		
	 ARTICLE 3 - REPORTS
	  	 	8	  
		
	 3.1 Mundipharma Sole Control
	  	 	8	  
	 3.2 Reports
	  	 	8	  
	 3.3 Safety
	  	 	8	  
		
	 ARTICLE 4 - DEVELOPMENT, COMMERCIALIZATION AND COOPERATION
	  	 	8	  
		
	 4.1 Transition Assistance
	  	 	8	  
	 4.2 Mundipharma Development Obligations
	  	 	9	  
	 4.3 Development Costs
	  	 	9	  
	 4.4 Commercialization
	  	 	9	  
	 4.5 Costs of Commercialization
	  	 	10	  
	 4.6 Report of Results, Data and Information
	  	 	10	  
	 4.7 Interactions with Government Agencies
	  	 	10	  
		
	 ARTICLE 5 - UNDERTAKINGS OF BIOCRYST AND MUNDIPHARMA
	  	 	10	  
		
	 5.1 Non-Use and Non-Disclosure
	  	 	10	  
	 5.2 Authorized Disclosure
	  	 	10	  
	 5.3 Manufacturing
	  	 	10	  
	 5.4 Maintenance of License
	  	 	10	  
		
	 ARTICLE 6 - PAYMENTS - ROYALTIES
	  	 	11	  
		
	 6.1 Payments Under Original Agreement
	  	 	11	  
	 6.2 Payments
	  	 	11	  
	 6.3 Royalties Payable by Mundipharma
	  	 	11	  
	 6.4 Royalty Reports
	  	 	12	  
	 6.5 Records
	  	 	12	  
	 6.6 Audit
	  	 	12	  
	 6.7 Foreign Currency Conversion
	  	 	12	  
	 6.8 Nature of Payments
	  	 	12	  
	 6.9 Payments to Third Parties
	  	 	12	  
		
	 ARTICLE 7 - TRADEMARKS AND DOMAIN NAMES
	  	 	12	  
		
	 7.1 Right to Use Trademarks
	  	 	12	  
	 7.2 Secondary Marks
	  	 	12	  

  
 i 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* *
*” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission 
 TABLE OF CONTENTS 
 (continued) 

 

					
	 	  	PAGE	 
		
	 7.3 Property in Trademarks and Payment of Fees
	  	 	13	  
	 7.4 Domain Names
	  	 	13	  
		
	 ARTICLE 8 - LITIGATION, PATENT PROSECUTION AND ROYALTY OFFSET
	  	 	13	  
		
	 8.1 Litigation
	  	 	13	  
	 8.2 Patent Prosecution
	  	 	14	  
	 8.3 Registration of Patent License
	  	 	14	  
	 8.4 Royalty Offset
	  	 	14	  
		
	 ARTICLE 9 - REPRESENTATIONS AND WARRANTIES
	  	 	15	  
		
	 9.1 BioCryst’s Representations and Warranties
	  	 	15	  
	 9.2 Mundipharma’s Representations and Warranties
	  	 	17	  
	 9.3 No other Representations
	  	 	17	  
	 9.4 Disclaimers
	  	 	18	  
		
	 ARTICLE 10 - INDEMNITY AND PRODUCT LIABILITY
	  	 	18	  
		
	 10.1 Indemnification and Defense by Mundipharma
	  	 	18	  
	 10.2 Indemnification and Defense by BioCryst
	  	 	18	  
	 10.3 Defense Procedures
	  	 	18	  
	 10.4 Insurance
	  	 	18	  
	 10.5 Survival
	  	 	19	  
	 10.6 Disclaimer of Liability for Consequential Damages
	  	 	19	  
		
	 ARTICLE 11 - TERM AND TERMINATION
	  	 	19	  
		
	 11.1 Term
	  	 	19	  
	 11.2 Termination by Parties
	  	 	19	  
	 11.3 Rights and Obligations of Parties upon Term Expiration or Termination
	  	 	20	  
		
	 ARTICLE 12 - DISPUTE RESOLUTION AND GOVERNING LAW
	  	 	21	  
		
	 12.1 Disputes
	  	 	21	  
	 12.2 Dispute Resolution
	  	 	22	  
	 12.3 Governing Law
	  	 	22	  
		
	 ARTICLE 13 - MISCELLANEOUS
	  	 	22	  
		
	 13.1 Mutual Release
	  	 	22	  
	 13.2 Covenants
	  	 	22	  
	 13.3 Non-Compete
	  	 	22	  
	 13.4 Delay of payment
	  	 	23	  
	 13.5 Assignment
	  	 	23	  
	 13.6 Pre-Existing Third Party License
	  	 	23	  
	 13.7 Press Releases and External Communications
	  	 	23	  
	 13.8 Use of Name
	  	 	23	  
	 13.9 Notices
	  	 	23	  
	 13.10 Effect of Waiver
	  	 	24	  

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* *
*” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission 
 TABLE OF CONTENTS 
 (continued) 

 

					
	 	  	PAGE	 
		
	 13.11 Effect of Partial Invalidity
	  	 	24	  
	 13.12 Force Majeure
	  	 	24	  
	 13.13 Entire Agreement; Amendment
	  	 	24	  
	 13.14 Status of Parties
	  	 	25	  
	 13.15 Further Assurances
	  	 	25	  
	 13.16 Performance by Associates
	  	 	25	  
	 13.17 Intellectual Property
	  	 	25	  
	 13.18 Counterparts; Facsimile Signature
	  	 	25	  

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* *
*” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission 
  

 AMENDED AND RESTATED LICENSE AND DEVELOPMENT AGREEMENT 

This Amended and Restated License and Development Agreement is made as of November 11, 2011 (the “Effective
Date”) by and between BioCryst Pharmaceuticals, Inc., a company organized and existing under the laws of Delaware having offices at 4505 Emperor Blvd, Suite 200 Durham, NC 27703 (“BioCryst”) and Mundipharma International
Corporation Limited, a Bermudan company, having offices at Mundipharma House, 14 Par-la-Ville Road, Hamilton, Bermuda HMJX (“Mundipharma”) (hereinafter, each of BioCryst and Mundipharma a “Party” and, collectively,
the “Parties”). 
 W I T N E S S E T H : 

WHEREAS, BioCryst owns or controls patents and know-how related to a series of proprietary compounds which act as PNP Inhibitors
(as defined below), including the compound known as BCX-1777. 
 WHEREAS, Mundipharma has expertise in the discovery,
development, manufacture and sale of pharmaceutical products. 
 WHEREAS, Mundipharma and BioCryst entered into a License
and Development Agreement dated as of February 1, 2006 (the “Original Agreement”) pursuant to which BioCryst granted to Mundipharma, in certain countries, rights and licenses relating to BCX-1777 under certain patents, know-how
and trademarks owned or controlled by BioCryst. 
 WHEREAS, certain disagreements developed between the Parties under the
Original Agreement. 
 WHEREAS, the Parties desire to settle such disagreements by releasing each other from all claims
relating thereto, and desire to re-affirm their license relationship by entering into this Agreement in place of the Original Agreement. 
 NOW, THEREFORE, in consideration of the mutual promises and covenants contained in this Agreement, the parties agree as follows: 

ARTICLE 1 - DEFINITIONS 
 As used in this Agreement, the following terms shall have the following meanings:. 

1.1 “Associate” of a Party means any person, firm, trust, corporation or other entity or combination thereof
which directly or indirectly (a) controls said Party, (b) is controlled by said Party, or (c) is under common control with said Party; the terms “control” and “controlled” meaning direct or indirect ownership
(including pursuant to any option, warrant or other arrangement or understanding) of fifty percent (50%) or more, including ownership by trusts with substantially the same beneficial interests, of the voting rights, shares or other equity
interests of such person, firm, trust, corporation or other entity or combination thereof or the power to direct the management of such person, firm, trust, corporation or other entity or combination thereof. 

1.2 “ATL” means adult T-cell leukaemia/lymphoma. 

1.3 “Autoimmune Indications” means all indications that involve pathogenic consequences, including tissue injury,
produced by autoantibodies or autoreactive T lymphocytes interacting with self epitopes, i.e. autoantigens. Autoimmune Indications shall include, without limitation, asthma, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma,
juvenile rheumatoid arthritis, polymyositis, ankylosing spondylitis, Type I diabetes, sarcoidosis, Sjogrens syndrome, chronic active non-pathogenic hepatitis, non-infectious uveitis (Behcet’s), aplastic anemia, hemolytic anemia, idiopathic
thrombocytopenia purpura, vasculitis, Hashimoto’s thyroiditis, atopic dermatitis, regional non-pathogenic enteritis (including ulcerative colitis, Crohn’s disease and inflammatory bowel disease), Kawasaki’s disease, post-infectious
encephalitis, myasthenia gravis, multiple sclerosis, alopecia and tropic spastic paraparesis. 

  
 Page 1

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* *
*” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission 
  

 1.4 “BCX-4208” means the PNP Inhibitor known as BCX-4208 having the
following chemical structure * * *. 
 1.5 “BCX-5235” means * * *. 

1.6 “BCX-5235 License Agreement” is defined in Section 2.5.1. 

1.7 “BioCryst Indemnitees” is defined in Section 10.1. 

1.8 “BioCryst Know-How” means all knowledge and proprietary information, including know-how, trade secrets, data,
technology and scientific and technical information now or hereafter during the Term owned, developed or controlled by BioCryst or any of its Associates, which relate to the Compound or the Licensed Products, including but not limited to:
(a) medical, clinical, toxicological or other scientific data, and (b) processes and analytical methodology useful in respect of the Initial Mundipharma Trials Plan, Mundipharma Trials Plan and/or the Development, testing, analysis,
manufacture or packaging of the Compound or the Licensed Products. 
 1.9 “BioCryst Patents” means those
patents and patent applications set forth on Schedule 1.9, and all patents and patent applications that claim priority to any of the foregoing or which claim the manufacture, use or sale of the Compound or Licensed Products in the Territory, in each
case which patent applications and patents are owned or controlled by BioCryst or its Associates, or as to which BioCryst or any of its Associates have a license with rights to sublicense, during the Term, and any extensions, supplementary
protection certificates, continuations, continuations-in-part, divisions, reissues, re-examinations, additions, substitutions, confirmations, registrations, or re-validations of or to any of the foregoing. 

1.10 “Business Day” means a day that is not a Saturday, Sunday or a day on which banking institutions in New
York, New York or London, England, are authorized by Legal Requirements to remain closed. 
 1.11 “Cancerous
State” means a state in which cells exhibit aberrant and uncontrolled proliferation that are believed to be malignant. 

1.12 “Claims” means any and all losses, liabilities, costs and expenses (including attorneys’ fees and
expenses), debts and other obligations arising out of or resulting from claims, judgments, damages of any kind whatsoever (including but not limited to compensatory, exemplary and punitive damages), arbitral awards, and amounts paid in settlement of
claims, judgments, legal (including but not limited to judicial, arbitral and administrative) proceedings and the like, which claims, judgments, damages, awards, settlements, legal proceedings and the like which arise out of or are connected or
related in any way whatsoever to the design or clinical investigation or research or testing or labeling or manufacturing or packaging or marketing or sale or distribution of the Compound or Licensed Products, including (but not limited to) physical
injury, death or product liability and similar Third Party claims. 
 1.13 “CLL” means chronic
lymphocytic leukaemia. 
 1.14 “Commercialization” means, with respect to the Licensed Products, any and
all processes and activities conducted to permit, establish, promote and maintain sales for the Licensed Products, including negotiating and obtaining Pricing Approvals, manufacturing, offering for sale, detailing, commercializing (including
launch), promoting, storing, transporting, supporting, distributing, and importing the Licensed Products, and all Phase IV and post-marketing studies and tests of such Licensed Products, but in all cases excluding the Initial Mundipharma Trials Plan
and any Mundipharma Trials Plan and Development. “Commercialize” and “Commercializing” shall have their correlative meanings. 
 1.15 “Commercially Reasonable Efforts” means with respect to the Initial Mundipharma Trials Plan and any Mundipharma Trials Plan a level of resources, efforts and urgency to
develop the Licensed Products in accordance with the Initial Mundipharma Trials Plan and any subsequent Mundipharma Trials Plan that is consistent with Mundipharma (or its Associates’) practices in diligently and actively pursuing clinical
trials in respect of its other pharmaceutical products at a similar stage of product life, and having similar safety, efficacy and commercial potential. Should Mundipharma, in its sole discretion, determine not to terminate this Agreement after

  
 Page 2

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* *
*” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission 
  

 
the Initial Mundipharma Trial Plan or any Mundipharma Trials Plan has been completed or otherwise ended, then Commercially Reasonable Efforts means with respect to (i) Development a level of
resources, efforts and urgency applied by Mundipharma to Develop the Licensed Products in accordance with Mundipharma’s current Development plan that is consistent with Mundipharma (or its Associates’) practices in diligently and actively
pursuing such development activities in respect of its other pharmaceutical products at a similar stage of product life, and having similar safety, efficacy and commercial potential; and (ii) Commercialization a level of resources, efforts and
urgency applied by Mundipharma in a country, following grant of both Regulatory Approval and Pricing Approval in a form satisfactory to Mundipharma, to Commercialize the Licensed Products in such country that is consistent with Mundipharma (or its
Associates’) practices in diligently and actively pursuing commercialization of its other pharmaceutical products at a similar stage of product life, and having similar safety, efficacy and commercial potential. It is understood that any such
resources, efforts and urgency may change from time to time during the Term based upon changing safety, efficacy, scientific, business and commercial considerations. 
 1.16 “Compound” means the PNP Inhibitor known as BCX-1777 as claimed in the BioCryst Patents having the following chemical structure 

 
 

 
 and including the salts, esters, metabolites, tautomers, isomers, conjugates and complexes thereof. 

1.17 “Compound Transfer” is defined in Section 4.1.2. 

1.18 “Confidential Information” means any and all information, data or know-how of a confidential nature
(including BioCryst Know-How and Mundipharma Know-How), whether financial, business, legal, technical or non-technical, oral or written, related to the Compound or the Licensed Products or otherwise related to a Party or its licensors that is
disclosed by one Party or its Associates (“Disclosing Party”) to the other Party or its Associates (“Receiving Party”). 
 Confidential Information shall not include any information which: 
 (i) either
before or after disclosure to the Receiving Party, was or becomes published or generally known to the public through no fault or omission on the part of the Receiving Party; or 

(ii) was known or used by the Receiving Party prior to its disclosure by the Disclosing Party to the Receiving Party; or 

(iii) either before or after disclosure to the Receiving Party, is provided to the Receiving Party without restriction by a Third Party
having the legal right to do so; or 
 (iv) is independently developed by the Receiving Party without access to or use of the
Disclosing Party’s Information; or 
 (v) is required to be disclosed by the Receiving Party to comply with applicable
laws, to defend or prosecute litigation or to comply with governmental regulations, provided that, the Receiving Party provides prior written notice of such disclosure to the Disclosing Party and, to the extent practicable, takes
reasonable and lawful actions to minimize the degree of such disclosure. 
 1.19 “Decision Period” is
defined in Section 8.1.4. 

  
 Page 3

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* *
*” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission 
  

 1.20 “Develop” means with respect to Mundipharma for the
Licensed Products, any and all processes and activities in accordance with a Mundipharma development plan subsequent to completion or termination of the Initial Mundipharma Trials Plan and any Mundipharma Trials Plan. “Develop”,
“Development” and “Developing” shall have their correlative meanings. 
 1.21 “U.S.
Dollars”, or “$” means dollars constituting legal tender for the payment of public and private debts in the United States of America. 
 1.22 “Effective Date” is defined in the preamble. 

1.23 “EMEA” means the European Agency for the Evaluation of Medicinal Products. 

1.24 “Field” means the treatment of all Cancerous and/or Pre-Cancerous States in humans. 

1.25 “First Commercial Sale” means the first shipment for commercial sale of a Licensed Product in the Territory
by Mundipharma or its Associates to a Third Party. 
 1.26 “Force Majeure Event” is defined in
Section 13.12. 
 1.27 “Foreign Currency Sales” is defined in Section 6.3.2. 

1.28 “Generic Compounds” means any pharmaceutical products, other than the Licensed Products, that (i) are
marketed for sale by a Third Party, * * *. 
 1.29 “Governmental Authority” means any court, agency,
department, authority or other instrumentality of any foreign, federal, state, county, city or other political subdivision. 

1.30 “Gross Price” means, with respect to a Licensed Product, the unit price, without deduction, actually
invoiced by Mundipharma, its sublicensees or its Associates for the sale of such Licensed Product. 
 1.31
“Hyperuricemea” means an excess of uric acid in the blood, whether or not symptoms of gout are present. 

1.32 “IND” means an Investigational New Drug Application under the U.S. Federal Food, Drug and Cosmetic Act, as
amended, and the regulations promulgated thereunder, or equivalent in another jurisdiction. 
 1.33 “Initial
Mundipharma Trials Plan” means with respect to Mundipharma, for the Licensed Product the conduct until the first interim analysis of * * *. 
 1.34 “Initiating Party” is defined in Section 8.1.6. 

1.35 “Legal Requirements” means all laws, statutes, rules, regulations, orders, decrees, judgments and/or
ordinances of any Governmental Authority and any present and future supra-national, national, state and local laws (including rules and regulations having the force of law); requirements under permits; orders, decrees, judgments and directives;
requirements of the Regulatory Authorities, including without limitation cGMPs, Council Regulation (EEC) No 2309/93, requirements imposed under the Federal Food, Drug and Cosmetic Act and the Public Health Service Act, each as amended from time to
time, requirements in 21 C.F.R. Part 312, applicable requirements in 21 C.F.R. Parts 600-680 and similar requirements of Regulatory Authorities in jurisdictions outside the United States. 

1.36 “Licensed Products” means all pharmaceutical preparations in all dosage strengths, formulations and methods
of administration that contain the Compound as its active ingredient, alone or in combination with another active ingredient. 

  
 Page 4

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* *
*” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission 
  

 1.37 “Licensed Products Sold” means sales of the Licensed
Products by Mundipharma or its Associates or its permitted Third Party sublicensees to Third Parties (other than Third Party sublicensees) in the Territory. 
 1.38 “Marketing Authorization” means the product license or marketing authorization necessary as a prerequisite for marketing and selling the Licensed Products in each country of
the Territory. 
 1.39 “Material Default” means, with respect to each Party: 

(i) any default by any Party hereto of its covenants, representations, agreements or other performance obligations under this Agreement (other than a
payment obligation) (a) that is a material breach or (b) that when aggregated with any other such uncured defaults by such Party, constitutes a material breach and, in the case of either clause (a) or (b), if such default is capable
of being cured, shall have continued for * * * (* * *) days after written notice thereof was provided to the alleged defaulting Party by the non-defaulting Party (or, if such default cannot be cured within such * * *-day period, if the alleged
defaulting Party does not promptly commence and diligently continue all reasonable actions to cure such defaults during such * * *-day period); or 
 (ii) any default by any Party hereto of its payment obligations hereunder that shall have continued for * * * (* * *) days after written notice thereof was provided to the alleged defaulting Party by the
non-defaulting Party. 
 1.40 “Mundipharma Indemnitees” is defined in Section 10.2. 

1.41 “Mundipharma Know-How” means all know-how, trade secrets, data, technology, scientific and technical
information, improvements and inventions, now or hereafter during the Term owned, developed or acquired by Mundipharma or any of its Associates, or by any Third Party on behalf of Mundipharma or its Associates, which relate to the Compound or the
Licensed Products, including but not limited to: (a) medical, clinical, toxicological or other scientific data, and (b) processes and analytical methodology useful in respect of the Mundipharma Trials Plan and/or the Development, testing,
analysis, manufacture or packaging of the Compound or the Licensed Products. 
 1.42 “Mundipharma
Notice” is defined in Section 2.5.1. 
 1.43 “Mundipharma Patents” means all patent
applications and patents which claim improvements upon or modifications to the inventions and discoveries disclosed or claimed in any of the BioCryst Patents or which claim the manufacture, use or sale of Compound or Licensed Products, which patent
applications and patents are owned or controlled by Mundipharma or its Associates, or as to which Mundipharma or any of its Associates have a license with rights to sublicense, during the Term, and any extensions, supplementary protection
certificates, continuations, continuations-in-part, divisions, reissues, re-examinations, additions, substitutions, confirmations, registrations, or re-validations of or to any of the foregoing. 

1.44 “Mundipharma Trials Plan” means with respect to Mundipharma, for the Licensed Product, any subsequent
Mundipharma Trials Plan for the development or Regulatory Approval of the Licensed Products which is provided to BioCryst after completion or termination of the Initial Mundipharma Trials Plan or a prior Mundipharma Trials Plan. 

1.45 “NDA” means a New Drug Application, including all supplements and amendments thereto, for the approval of a
Licensed Product as a new drug under the U.S. Federal Food, Drug and Cosmetic Act, as amended, or equivalent in another jurisdiction, and the regulations promulgated thereunder filed with a Regulatory Authority. 

1.46 “Net Sales” means (a) the Gross Price of Licensed Products multiplied by the quantity of Licensed
Products Sold at such Gross Price LESS, only as specifically applicable to Licensed Products Sold, (b) the sum of * * *. 
 1.47 “New Indications” means any indication outside the Field (excluding hyperuricemia and gout). 
 1.48 “Original Agreement” is defined in the recitals. 

  
 Page 5

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* *
*” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission 
  

 1.49 “Patent Activities” is defined in Section 8.2.1.

 1.50 “Payments” is defined in Section 6.2. 

1.51 “Phase II” means a human clinical trial performed to evaluate the efficacy of a Licensed Product for a
particular indication or indications in patients with the disease or condition under study and/or to determine the common short-term side effects and risks associated with the drug, as described in 21 C.F.R. Part 312, as it may be amended.

 1.52 “PNP Inhibitor” means * * *. 

1.53 “Pre-Cancerous State” means any abnormal proliferation of cells exhibiting features characteristic of cancer
that are of genetic or iatrogenic origin but are not in a Cancerous State, including without limitation actinic keratosis, Barrett’s oesophagus, cervical intraepithelial neoplasia, colonic polyposis, lymphomatoid papulosis, lymphomatoid
granulomatosis, oral leukoplakia, other lymphoproliferative disorders, Putz-Jeghers Syndrome, Purtilo Syndrome and Xeroderma Pigmentosum. 
 1.54 “Pre-Existing Third Party License” means the agreement dated June 27, 2000 by and between, on the one hand, Albert Einstein College of Medicine of Yeshiva University, a
division of Yeshiva University and Industrial Research Ltd., and on the other hand BioCryst, as amended on July 26, 2002 and on April 15, 2005, December 11, 2009, May 5, 2010 and as may be amended after the Effective
Date. 
 1.55 “Pricing Approval” means, in a country of the Territory where a Governmental Authority or
non-governmental body with relevant statutory authority approves or, thereafter, determines pricing for pharmaceutical products for reimbursement or otherwise, such approval or determination. 

1.56 “PTCL” means peripheral T-cell lymphoma. 

1.57 “Regulatory Approval” with respect to a particular jurisdiction in the Territory and Licensed Product means
the receipt of all regulatory approvals necessary for sale of the Licensed Product in that jurisdiction, but excluding Pricing Approval. 
 1.58 “Regulatory Authority” means the FDA, or in the case of a jurisdiction outside of the United States, such corollary or other appropriate Regulatory Authority with similar
responsibilities, including, without limitation, the EMEA. 
 1.59 “Secondary Marks” is defined in
Section 7.2. 
 1.60 “SLT” or “Second-Line Treatment” means the treatment of
patients that have been previously treated for cancer, but have had a refraction or relapse of cancer. 
 1.61
“Stem-Cell Transplantation” means a procedure in which healthy stem cells are infused to help restore normal bone marrow function. 
 1.62 “Suit Notice” is defined in Section 8.1.4. 

1.63 “Term” has the meaning defined in Section 11.1.1. 

1.64 “Territory” means the world. 
 1.65 “Third Party(ies)” shall mean any party other than BioCryst, Mundipharma and their respective Associates from time to time. 

1.66 “Trademarks” means the trademarks “Fodosine” and “Fodozan”. 

1.67 “Transition Assistance Schedule” is defined in Section 4.1. 

  
 Page 6

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* *
*” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission 
  

 1.68 “Transplantation Indications” means all indications that
involve the suppression of rejection of transplanted organs, bone marrow or other tissue, including, without limitation, solid organ transplantation (including tolerance induction and xenotransplantation), bone marrow transplantation, graft versus
host disease and cell transplantation. 
 1.69 “Valid Claim” means any claim in an issued and unexpired
patent included within Schedule 1.9 which has not been revoked or held unenforceable or invalid by a final, non-appealable decision of a court of other Governmental Authority of competent jurisdiction. 

1.70 Interpretations. The definitions of the terms herein apply equally to the singular and plural forms of the terms defined.
Whenever the context may require, any pronoun will include the corresponding masculine, feminine and neuter forms. The words “include”, “includes” and “including” will be deemed to be followed by the phrase
“without limitation.” Unless the context requires otherwise, (A) any definition of or reference to any agreement, instrument or other document herein will be construed as referring to such agreement, instrument or other document as
from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein or therein), (B) any reference to any laws herein will be construed as referring to
such laws as from time to time enacted, repealed or amended, (C) any reference herein to any person will be construed to include the person’s permitted successors and assigns, (D) the words “herein”, “hereof” and
“hereunder”, and words of similar import, will be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (E) any reference herein to the words “mutually agree” or “mutual
written agreement” will not impose any obligation on either Party to agree to any terms relating thereto, and (F) all references herein to Articles, Sections, Exhibits or Schedules will be construed to refer to Articles, Sections, Exhibits
and Schedules of this Agreement. The table of contents, captions and Section headings appearing in this Agreement are inserted only as a matter of convenience and in no way define, limit, construe or describe the scope or intent of such Sections or
of this Agreement, nor in any way affect this Agreement. 
 ARTICLE 2 - GRANT 

2.1 License Grants. Subject to the rights retained by BioCryst and its licensors as set forth in Section 2.2, BioCryst grants
to Mundipharma an exclusive, royalty-bearing, right and license in the Territory, with the right to sublicense without the consent of BioCryst (provided that such sublicensees agree in writing to be bound by all of the terms of this Agreement and no
Third Party sublicensee shall have the right to further sublicense rights), to develop, register, make, have made, package and have packaged, use, promote, market, offer for sale, sell and import Licensed Products in the Field, in each case under
the BioCryst Patents and BioCryst Know-How. Where Mundipharma has an obligation to the licensors of the Pre-Existing Third Party License to seek their consent for a sub-license, it shall give BioCryst the first opportunity to approach the said
licensors on Mundipharma’s behalf to obtain such consent. 
 2.2 BioCryst Retained Rights. BioCryst retains all of
the following rights: 
 2.2.1 subject to Section 2.3, all rights under the BioCryst Patents and the BioCryst
Know-How outside of the Field; 
 2.2.2 the rights reserved to the licensors and the governments under the Pre-Existing
Third Party License; 
 2.2.3 the right to conduct or continue further non-commercial research into the Licensed Products
and/or the Compound, but not to conduct pre-clinical or clinical trials into the Licensed Products and/or the Compound without Mundipharma’s prior written consent; and 
 2.2.4 all rights with respect to BCX-5235 other than as explicitly set forth in Section 2.5. 
 2.3 Mundipharma Exclusive Option. In further consideration of the commitments made and payments to be made under this Agreement, BioCryst hereby grants to Mundipharma an exclusive option during the
Term to negotiate a new license agreement to conduct research with, develop and commercialize the Compound and Licensed Products in New Indications, upon terms mutually agreeable to both parties, as

  
 Page 7

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* *
*” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission 
  

 
determined by each party in its sole discretion. Such negotiations shall be conducted by both Parties in good faith. BioCryst further agrees, subject to Section 2.2.3, that during the Term
it shall not, and shall not grant rights to an Associate or Third Party to, develop, register, make, package, use, promote, market, offer for sale, sell or commercialize the Compound or Licensed Products in an indication outside the Field.

 2.4 BCX-4208. In further consideration of the commitments made and payments to be made under this Agreement, BioCryst
agrees that during the Term it shall not, and shall not grant rights to an Associate or a Third Party to, develop, make, use, sell or commercialize pharmaceutical products containing BCX-4208 within the Field. Notwithstanding the foregoing and for
the purposes of clarity, it is understood and agreed that (i) no rights related to BCX-4208 are granted to Mundipharma in this Agreement and (ii) the Field does not include Autoimmune Indications, Stem-Cell Transplantation, Transplantation
Indications and Hyperuricemia. 
 2.5 BCX-5235. During the Term of this Agreement, BioCryst shall be obligated to
negotiate with Mundipharma to grant it a license to BCX-5235 in accordance with this Section 2.5. 
 2.5.1 * * *.

 2.5.2 * * *. 
 2.5.3 In the context of Sections 2.3, 2.5.1, and 2.5.2, ‘good faith’ shall include the use of commercially reasonable efforts to reach agreement of terms which are mutually acceptable to
both Parties. 
 2.6 Mundipharma Research Outside the Field. Mundipharma shall not engage and shall not permit a Third
Party to engage in any research outside the Field without BioCryst’s consent in accordance with this Section 2.6. In the event that Mundipharma desires to conduct certain in vitro studies or proof of concept in vivo studies with the
Licensed Products in New Indications, or to supply Licensed Products to a Third Party investigator to permit him to do so, then Mundipharma shall first provide to BioCryst a detailed written description of the proposed studies along with any other
information that BioCryst reasonably requests with respect to such studies. Upon receipt of sufficient information from Mundipharma, BioCryst shall determine, in its sole discretion, whether or not such studies could potentially have a negative
impact on its PNP inhibitor compounds generally. In the event BioCryst determines that no potential for negative impact exists, then BioCryst’s consent for such studies shall not be unreasonably withheld. 

ARTICLE 3 - REPORTS 
 3.1 Mundipharma Sole Control. It shall be agreed and understood that Mundipharma shall control all aspects of the development and Commercialization of the Compound and Licensed Products in the
Territory. 
 3.2 Reports. During the Term of this Agreement, Mundipharma will provide semi-annual reports to BioCryst,
with the first report due six (6) months after the Effective Date, regarding the Development and Commercialization of the Compound and Licensed Products which shall contain a summary of the progress of the Mundipharma Trials Plan, Development
and Commercialization of the Compound and Licensed Products, copies of publications, copies of published Mundipharma Patents and safety information related to the Compound and the Licensed Product. 

3.3 Safety. If either Party becomes aware of a safety signal, not previously known, which may materially impact PNP Inhibitors as
a class, then such Party will promptly provide such information to the other Party in sufficient detail to allow a reasonable evaluation of the information. 
 ARTICLE 4 - DEVELOPMENT, COMMERCIALIZATION AND COOPERATION 
 4.1
Transition Assistance. Notwithstanding anything set forth in the Original Agreement to the contrary, as of the Effective Date, BioCryst shall have no further obligation to, and shall not in future, develop or commercialize the Licensed Products.
As such, the Parties shall cooperate to facilitate and enable the transfer of certain activities and all data relating to the Compound and Licensed Products to Mundipharma in the Territory pursuant to the conditions and protocols set forth on
Schedule 4.1 (the “Transition Assistance Schedule”). In addition to each Party’s obligations pursuant to the Transition Assistance Schedule, the Parties hereby agree that: 

4.1.1 BioCryst Technical Assistance. During the transfer process of the data as specified on Schedule 4.1 and for a period of
sixty (60) days thereafter, BioCryst shall render to Mundipharma technical assistance as may be reasonably required in transferring all aspects of the development program for the Licensed Product to Mundipharma and as otherwise agreed upon by
the Parties in writing. Thereafter, BioCryst shall be reasonably compensated for any additional technical assistance provided to Mundipharma to further the development and Commercialization of the Licensed Products. 

  
 Page 8

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* *
*” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission 
  

 4.1.2 Purchase of Supplies. No later than fifteen (15) business days after
the Effective Date BioCryst shall deliver and Mundipharma shall take possession of and purchase (at * * *) lots * * * of the Compound, as more particularly described in Schedule 4.1.2 (“Compound Transfer”). Upon completion of the
Compound Transfer, BioCryst shall have no further obligation to supply to Mundipharma any other materials or compounds relating to, or associated with, the Licensed Products. Any Compound delivered to Mundipharma hereunder shall be accompanied by a
Certificate of Analysis from the manufacturer. Mundipharma will be entitled, at its cost and expense to test the Compound delivered to Mundipharma hereunder to determine whether such Compound complies with the specifications as set forth in Schedule
4.1.2. Mundipharma shall have until * * * or * * * (* * *) calendar days from the date of receipt of Compound, whichever is the later, to inspect and reject acceptance by written notice to BioCryst; provided, however, that any such notice shall set
forth the reason for such rejection. If BioCryst does not receive Mundipharma’s written notice of rejection by * * *, or within * * * (* * *) calendar days from receipt of the Compound, whichever is the later, Mundipharma shall be deemed to
have accepted the Compound. Mundipharma’s sole remedy for Compound which does not meet the specifications shall be a refund of amounts paid by Mundipharma for such Compound.  

4.1.3 Future Data. BioCryst shall promptly during the Term provide all new BioCryst Know-How and any other data related to the
Compound or the Licensed Products arising after the Effective Date to Mundipharma. 
 4.2 Mundipharma Development
Obligations. Mundipharma will use Commercially Reasonable Efforts to undertake the Initial Mundipharma Trials Plan. Should Mundipharma, in its sole discretion, determine not to terminate this Agreement after the Initial Mundipharma Trials Plan
has been completed or otherwise ended, Mundipharma shall submit to BioCryst a new Mundipharma Trials Plan for continued development of the Licensed Product. Upon completion or termination of any Mundipharma Trials Plan, Mundipharma shall, within a
reasonable period of time after completion or termination of such Mundipharma Trials Plan, either terminate the Agreement or provide a new Mundipharma Trials Plan to BioCryst to continue development of the Licensed Product; provided, however, that
upon completion or termination of the last Mundipharma Trials Plan, Mundipharma shall either terminate the Agreement or use Commercially Reasonable Efforts to Develop and Commercialize the Licensed Products in the Territory in compliance with Legal
Requirements. The Parties acknowledge and agree that Mundipharma shall have no other obligation in respect of the development or Commercialization of the Compound or Licensed Products and shall be entitled to terminate this Agreement, at its sole
discretion, in accordance with Section 11.2.3.3 at any time. 
 4.3 Development Costs. All Development costs
incurred on or after the Effective Date shall be borne by Mundipharma. 
 4.4 Commercialization. 

4.4.1 Mundipharma shall notify BioCryst within five (5) days of the date of the First Commercial Sale of a Licensed Product
in each country within the Territory. 
 4.4.2 Mundipharma is entitled to engage contract sales organizations to
supplement or complement Mundipharma’s sales force in the Territory, provided that Mundipharma shall at all times remain primarily responsible and liable for all such activities as if such activities had been undertaken by Mundipharma.

 4.4.3 * * *. 

  
 Page 9

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* *
*” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission 
  

 4.5 Costs of Commercialization. Mundipharma or its Associates shall be
responsible for all costs associated with the Commercialization of Licensed Products within the Territory. 
 4.6 Report of
Results, Data and Information. 
 All preclinical and clinical data generated by or on behalf of Mundipharma beginning as of the Effective
Date of this Agreement shall be owned by Mundipharma and shall constitute a part of Mundipharma’s Know-How. All preclinical and clinical data generated by or on behalf of Mundipharma prior to the Effective Date of this Agreement shall be
governed by the terms of the Original Agreement as if the Original Agreement remained in force. 
 4.7 Interactions with
Government Agencies. 
 4.7.1 Following the transfer of responsibility pursuant to Schedule 4.1, Mundipharma shall be
solely responsible for the collection, review, assessment, tracking and filing with appropriate Regulatory Authorities of information related to adverse events associated with the Licensed Products in accordance with applicable FDA regulations,
including without limitation 21 CFR §§ 312.32, 314.80, and with comparable Legal Requirements in relevant countries within the Territory. In accordance with Schedule 4.1, BioCryst shall transfer its global safety database for the Licensed
Products to Mundipharma’s designee together with all other information and data in BioCryst’s possession or control which is relevant or useful in assisting Mundipharma to fulfill its responsibility pursuant to this Section 4.7.
BioCryst shall in future forward any information related to adverse events associated with the Licensed Products to Mundipharma’s designee immediately upon receipt. 
 4.7.2 Governmental Authority Inquiries. Mundipharma shall notify BioCryst within two (2) Business Days after it receives information about the initiation of any investigation, review or
inquiry by the FDA, EMEA or other Governmental Authority concerning (i) non-clinical or clinical research relating to the Compound or the Licensed Product; or (ii) the Commercialization of the Licensed Products. 

ARTICLE 5 - UNDERTAKINGS OF BIOCRYST AND MUNDIPHARMA 

5.1 Non-Use and Non-Disclosure. During the Term and thereafter, a Receiving Party shall (i) treat Confidential Information
provided by Disclosing Party as it would treat its own information of a similar nature, (ii) take all reasonable precautions not to disclose such Confidential Information to Third Parties without the Disclosing Party’s prior written
consent, and (iii) not use such Confidential Information other than in accordance with the terms of this Agreement. All information related to BioCryst’s licensors and the Pre-Existing Third Party License shall be deemed to be BioCryst
Confidential Information. 
 5.2 Authorized Disclosure. Nothing in this Agreement shall prevent Mundipharma or its
Associates from disclosing Confidential Information to (i) Governmental Authorities of any country to the extent required or desirable to secure government approval for the development, manufacture or Commercialization of Licensed Products,
(ii) Third Parties acting on behalf of Mundipharma or its Associates, to the extent reasonably necessary for the development, manufacture or Commercialization of Licensed Products (and provided that Mundipharma has a written confidentiality
agreement with such Third Party which is as protective of such Confidential Information as the terms of this Agreement), or (iii) Third Parties to the extent reasonably necessary to market Licensed Products (and provided that Mundipharma has a
written confidentiality agreement with such Third Party which is as protective of such Confidential Information as the terms of this Agreement). Each Party shall be ultimately responsible for compliance with the terms of this Article 5 by its
Associates, or any Third Party who receives Confidential Information as a result of a disclosure of such Confidential Information initially made by such Party. 
 5.3 Manufacturing. Mundipharma shall have sole responsibility (including complete decision making authority and discretion) to manufacture or have manufactured the Licensed Products for the
Mundipharma Trials Plan and Development (including clinical trial material) and Commercialization by Mundipharma or its Associates in the Field. Manufacturing of the Licensed Product shall be conducted in accordance with cGMP. 

5.4 Maintenance of License. * * *. 

  
 Page 10

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* *
*” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission 
  

 ARTICLE 6 - PAYMENTS - ROYALTIES 

6.1 Payments Under Original Agreement. The Parties acknowledge and agree that all payments made under the Original Agreement are
non-refundable and non-creditable and that no further payments are due by either Party under the Original Agreement. 
 6.2
Payments. As partial consideration for the licenses granted by BioCryst to Mundipharma, Mundipharma shall pay to BioCryst the following one-time payment amounts (each a “Payment” and collectively the “Payments”)
in U.S. Dollars listed in the table below. 
  

			
	 Event
	  	Payment
Amount
	Regulatory Approval for * * *	  	$* * *
	Regulatory Approval for * * *.	  	$* * *

 6.2.1 Each such Payment shall be deemed earned as of the achievement of the corresponding event
set forth above and shall be paid by Mundipharma within * * * (* * *) days after achievement of such event. 
 6.2.2 It
is understood and agreed between the Parties that, subject to Section 5.4, the above Payments shall be non-refundable and non-creditable. 
 6.3 Royalties Payable by Mundipharma. In partial consideration for the licenses granted to Mundipharma, and subject to Sections 5.4, 8.1.3 and 8.4, Mundipharma shall pay to BioCryst: 

6.3.1 a royalty equal to * * *. 
 6.3.2 Remittance of Royalties. Payments due under Section 6.3 shall be due quarterly on a calendar basis, in arrears, and shall be payable no later than * * * (* * *) days after the last
Business Day of each such quarter. The payments due and payable under Section 6.3 shall be computed for each quarter with sales that occur in a currency other than U.S. Dollars (“Foreign Currency Sales”) to be converted in
accordance with Section 6.7. All payments made by Mundipharma pursuant to this Section shall be made in immediately available funds by wire transfer to such bank and account of BioCryst as may be designated from time to time by BioCryst.

 6.3.3 Deductions From Royalties. Mundipharma shall pay or procure the payment of the Royalties and other monies
payable to BioCryst under this Agreement from Bermuda. As of the Effective Date, there is no Legal Requirement in Bermuda for Mundipharma to pay or withhold of any income or other taxes on behalf of BioCryst with respect to Royalties and any other
monies payable to BioCryst under this Agreement. In the event that after the Effective Date, the payor of such Royalties and other monies payable to BioCryst under this Agreement shall change to an Associate of Mundipharma located in a jurisdiction
with respect to which such payment or withholding is required by applicable Legal Requirements, then such income or other taxes shall be deducted from the amount of such payments, royalties and other monies due to BioCryst and paid to the relevant
competent taxing authority; provided that (i) Mundipharma shall promptly notify BioCryst of such Legal Requirements in advance of the payment requiring the withholding; (ii) the sum payable shall be increased as necessary so that after
making all required deductions, BioCryst receives an amount equal to the sum it would have received had no withholding been made; and (iii) Mundipharma shall furnish BioCryst with proof of such payments. Mundipharma shall promptly provide
BioCryst with any available certificate or other documentary evidence that might enable BioCryst to support a claim for a refund or a foreign tax credit with respect to any such tax so withheld or deducted by Mundipharma, and BioCryst shall promptly
(a) file a claim for refund with the relevant taxing authority and (b) pay to Mundipharma the actual amount of any refund received. Mundipharma and BioCryst will reasonably cooperate in completing and filing documents required under the
provisions of any applicable tax treaty or under any other applicable law and to take any other reasonable actions, in order to enable Mundipharma to make such payments to BioCryst without any deduction or withholding, if possible consistent with
Legal Requirements (including by maintaining or changing, as reasonably necessary, the payor of amounts under this Agreement). 

  
 Page 11

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* *
*” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission 
  

 6.4 Royalty Reports. Each payment made to BioCryst under Section 6.3 shall
be accompanied by a written report, showing Gross Price and Net Sales and the calculation of the same (including all deductions taken to arrive at Net Sales) together with the calculation of the royalties due for the quarter for which payment is
being made. The report shall detail the amount of Licensed Products Sold, identified on a country-by-country basis. 
 6.5
Records. Mundipharma shall, and shall cause its Associates to, keep and maintain for * * * (* * *) years after payment of royalties pursuant to Section 6.3 complete and accurate books and records in sufficient detail so that Net Sales and
royalties payable hereunder can be properly verified. 
 6.6 Audit. No more frequently than once during each calendar
year during the Term and for * * * (* * *) years thereafter, Mundipharma shall permit independent auditors appointed by BioCryst, to whom Mundipharma has no reasonable objection and with reasonable notice at any time during normal business hours, to
inspect, audit and copy relevant accounts and records of such Party for the purpose of verifying the accuracy of the calculation of royalty payments to BioCryst and the reports which accompanied them. The independent auditors shall not disclose to
BioCryst any information other than information relating solely to the accuracy of the accounting and payments made by Mundipharma. If such audit determines that payments are due to BioCryst, Mundipharma shall pay to BioCryst any such additional
amounts within * * * (* * *) days of the date on which such auditor’s written report is delivered to Mundipharma, unless such audit report is disputed, in which case the dispute shall be resolved in accordance with Article 12. If the auditor
determines that Mundipharma’s payments are in excess of those required under this Agreement, BioCryst shall remit the difference to Mundipharma of such amount within * * * (* * *) days of the date on which such auditor’s report
is delivered, unless such audit report is disputed, in which case the dispute shall be resolved in accordance with Article 12. Any such inspection of records shall be at BioCryst’s expense unless such audit discloses an underpayment of any
payment of more than * * * percent (* * *%), in which case Mundipharma shall bear the cost of such audit. All payments due shall bear interest calculated as set forth in Section 13.4 below. 

6.7 Foreign Currency Conversion. Payments made under this Agreement shall be payable in U.S. Dollars. The payments due and payable
under Section 6.3 of this Agreement shall be computed for each calendar quarter with Foreign Currency Sales converted into U.S. Dollars using Mundipharma’s standard accounting procedures, consistently applied, which as of the Effective
Date is calculated at the average of the daily foreign exchange mid-range rates, as quoted in the Bloomberg Financial Network (or another publication as notified by Mundipharma to BioCryst in writing), for such calendar quarter. 

6.8 Nature of Payments. Subject to Sections 5.4, 8.1.3 and 8.4 all payments made pursuant to Section 6 shall be nonrefundable
and noncreditable. 
 6.9 Payments to Third Parties. BioCryst shall maintain the Pre-Existing Third Party License at its
own cost. In the event that a final court order or other binding order or ruling requires the payment of a royalty or other payment to a Third Party patent holder in respect of sales of the Licensed Products in the Territory (other than pursuant to
the Pre-Existing Third Party License), Mundipharma shall pay such royalty or other payments in exchange for a grant of all licenses from such Third Party necessary to make, have made, use, offer for sale, sell or import Licensed Products in the
Territory, with such royalty or other payment to be shared with BioCryst in accordance with Section 8.4. 
 ARTICLE 7
- TRADEMARKS AND DOMAIN NAMES 
 7.1 Right to Use Trademarks. Mundipharma shall have the exclusive right to use
the Trademarks and BioCryst shall assign and transfer to Mundipharma or its designees the Trademarks, including all applications to register the Trademarks and all registrations thereof, and all goodwill relating to the Trademark to Mundipharma or
its nominee. BioCryst shall execute in a timely fashion all documents reasonably required by Mundipharma to effect such assignments and transfers throughout the Territory. 
 7.2 Secondary Marks. At its discretion, Mundipharma may choose a new trademark (each such new trademark a “Secondary Mark”, and collectively the “Secondary Marks”)
under which to develop and Commercialize the Licensed Products. Mundipharma will be entitled to file, maintain, and/or renew an application or registrations for such Secondary Marks at Mundipharma’s expense, in its own name in such country(ies)
of the Territory. 

  
 Page 12

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* *
*” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission 
  

 7.3 Property in Trademarks and Payment of Fees. As of the Effective Date, the
Trademarks shall be the sole and exclusive property of Mundipharma or its nominees and Mundipharma or its Associates shall pay all fees falling due in future on the renewal of the Trademarks in the Territory. BioCryst shall cooperate with
Mundipharma as Mundipharma may reasonably request in furtherance of Mundipharma’s application, prosecution, registration, or maintenance of any filings for the Trademarks and all Secondary Marks throughout the Territory. 

7.4 Domain Names. Mundipharma shall have the right, at its expense, to apply for, acquire, register, maintain and use in the
Territory any domain names specific to countries in the Territory that incorporate the Trademarks or are used primarily in connection with the Licensed Products. 
 ARTICLE 8 - LITIGATION, PATENT PROSECUTION AND ROYALTY OFFSET 

8.1 Litigation. 
 8.1.1 Each Party shall promptly notify the other in writing (i) of any suspected or threatened infringement of a BioCryst Patent or a Mundipharma Patent by a Third Party in the Territory and
in the Field, (ii) of any known or suspected unauthorized use or misappropriation by a Third Party of any BioCryst Know-How or any Mundipharma Know-How in the Territory and in the Field; and (iii) of any assertion or claim of alleged
patent infringement by Mundipharma or its Associates with respect to the development, Commercialization, manufacture, use, sale, offer for sale or importation of the Compound or the Licensed Products in the Territory, and shall provide the other
Party with all evidence in its possession that tends to prove the Third Party infringement or unauthorized use or misappropriation described in clauses (i) or (ii); or that tends to negate the alleged infringement described in clause (iii); in
the case of each of clauses (i), (ii) and (iii), to the extent such Party becomes aware of it. 
 8.1.2 BioCryst
shall promptly advise Mundipharma of any events of which BioCryst becomes aware that may have a material bearing on the validity or enforceability of the BioCryst Patents in the Field and in the Territory and shall inform Mundipharma of
BioCryst’s plan, if any, to commence proceedings or to take other appropriate action in response to such events. BioCryst shall consider Mundipharma’s advice and comments in good faith. 

8.1.3 If Mundipharma or any of its Associates becomes a party to a suit by a Third Party in any country of the Territory and it is
alleged in the suit that Mundipharma’s or its Associate’s actions in the Territory with regards to Licensed Products infringe the Third Party’s intellectual property rights, then until such litigation is concluded, * * *% of the
royalties from said country that may accrue after the institution of such suit shall be paid to BioCryst, and the other * * *% of such royalties shall be placed in a separate fund hereinafter referred to as a “Defense Fund”.
Mundipharma may draw against such Defense Fund to satisfy therefrom all of the reasonable expenses of defending such suit as well as any damages that might be awarded or agreed upon. Any monies that accrue to the Defense Fund that are not required
to satisfy such expenses and/or damages and/or agreed settlement in such litigation shall be paid to BioCryst within * * * (* * *) days after the non-appealable conclusion of such litigation. 

8.1.4 Within a period of * * * (* * *) days after Mundipharma provides or receives written notice under 8.1.1 (“Decision
Period”), Mundipharma, in its sole discretion, shall decide whether or not to initiate a suit or take other appropriate action in the Field and in the Territory and shall notify BioCryst in writing of its decision (“Suit
Notice”). The Suit Notice shall provide a description of the suit or action contemplated by Mundipharma and shall provide details concerning the causes of action and grounds therefor. 

8.1.5 * * *. 
 8.1.6 Upon written request, the Party bringing suit or taking action in the Territory and in the Field (“Initiating Party”) shall keep the other Party informed of the status of any
such suit or action and shall provide the other Party with copies of all substantive documents and communications filed in such suit or action. The Initiating Party shall have the sole and exclusive right to select counsel for any such suit or
action. 

  
 Page 13

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* *
*” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission 
  

 8.1.7 The Initiating Party shall, except as provided below, pay all expenses of
the suit or action, including, without limitation, the Initiating Party’s attorneys’ fees and court costs. Mundipharma shall be entitled to * * * per cent (* * *%) of any damages, settlement fees or other consideration received
as a result of a suit or action initiated by either Party net of each Party’s actual counsel fees and out-of-pocket expenses, subject to payment of a royalty to BioCryst at the royalty rate then applicable pursuant to Section 6.3 on the
net amount received by Mundipharma. The balance of * * * per cent of the damages, settlement fees or other consideration received as a result of a suit or action by either Party, net of each Party’s actual counsel fees and out-of-pocket
expenses, shall be paid by BioCryst to the licensors under the Pre-Existing Third Party License Agreement for so long as BioCryst has an obligation to make such a payment under the Pre-Existing Third Party License Agreement. Once the obligation to
make such a payment under the Pre-Existing Third Party License Agreement has expired, Mundipharma shall retain * * * per cent (* * *%) of such damages, settlement fees or other consideration and pay a royalty to BioCryst at the royalty rate then
applicable pursuant to Section 6.3 on such amount net of each Party’s actual counsel fees and out-of-pocket expenses. 

8.1.8 If the Initiating Party believes it reasonably necessary, upon written request the other Party shall join as a Party to the
suit or action but shall be under no obligation to participate except to the extent that such participation is required as the result of its being named a Party to the suit or action. At the Initiating Party’s written request, the other Party
shall offer reasonable assistance to the Initiating Party in connection therewith at no charge to the Initiating Party except for reimbursement of reasonable out-of-pocket expenses incurred by the other Party in rendering such assistance. The other
Party shall have the right to participate and be represented in any such suit or action by its own counsel at its own expense. 

8.1.9 When Mundipharma is the Initiating Party, Mundipharma shall not settle, consent to judgment or otherwise voluntarily dispose
of the suit or action without the prior written consent of BioCryst, which consent shall not be unreasonably withheld. When BioCryst is the Initiating Party, BioCryst shall not settle, consent to judgment or otherwise voluntarily dispose of the suit
or action without discussing such action with Mundipharma and considering any objection by Mundipharma in good faith. 
 8.2
Patent Prosecution. 
 8.2.1 BioCryst shall prepare, file, prosecute and maintain (hereinafter “Patent
Activities”) the BioCryst Patents in the Territory, and Mundipharma shall reimburse BioCryst for its reasonable expenses incurred after the Effective Date in relation thereto (including, but not limited to, official patent office fees,
attorney fees, and out-of-pocket expenses). BioCryst shall consult with Mundipharma as to the Patent Activities, and shall furnish to Mundipharma copies of all substantive documents relevant to the Patent Activities for the BioCryst Patents, all in
sufficient time (at least one week) before any action by BioCryst is due, to allow Mundipharma to provide comments thereon. BioCryst shall consider Mundipharma’s comments in good faith. Mundipharma shall cooperate with BioCryst in all
reasonable ways in connection with the Patent Activities for the BioCryst Patents. 
 8.2.2 Mundipharma shall conduct the
Patent Activities in respect of the Mundipharma Patents at its own discretion and expense in the Territory. 
 8.3
Registration of Patent License. Upon Mundipharma’s request, the Parties shall enter into an appropriate memorandum of this license mutually agreed by the Parties which shall be recorded, as required or appropriate, in the patent or
governmental office of any country or countries in the Territory in which BioCryst has a patent pending or granted. 
 8.4
Royalty Offset. If Mundipharma shall be subject to a final court or other binding order or ruling requiring the payment of a royalty or other payment to a Third Party holding patents to the Compound itself, but not to formulations of the
Compound or methods of use or administration, or if the parties mutually agree in good faith that it is in the parties’ best commercial interests to settle a Third Party patent infringement proceeding initiated against Mundipharma or its
Associates in the Territory on the basis of patents to the Compound itself, but not formulations of the Compound or methods of use or administration, by taking a license from a Third Party patent holder in any country in exchange for a royalty or
other payment in respect of sales of the Licensed Products, then the amount of Mundipharma’s royalty payments to BioCryst under Section 6.3 with respect to Net Sales shall be reduced by the amount of the royalty or other payment made to
such Third Party patent holder pursuant to such order, ruling or license, but in no event shall such reduction exceed * * * percent (* * *%) of such royalties payable to BioCryst. 

  
 Page 14

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* *
*” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission 
  

 ARTICLE 9 - REPRESENTATIONS AND WARRANTIES 

9.1 BioCryst’s Representations and Warranties. BioCryst hereby represents and warrants the following to Mundipharma as of the
Effective Date : 
 9.1.1 BioCryst is a company duly organized, validly existing, and in good standing under the laws of
Delaware, with its principal place of business as indicated in the preamble of this Agreement. BioCryst (i) is duly qualified as a corporation and in good standing under the laws of each jurisdiction where its ownership or lease of property or
the conduct of its business requires such qualification, where the failure to be so qualified would have a material adverse effect on its financial condition or its ability to perform its obligations under this Agreement; (ii) has the requisite
corporate power and authority and the legal right to conduct its business as now conducted and hereafter contemplated to be conducted; (iii) has all necessary licenses, permits, consents, or approvals from or by, and has made all necessary
notices to, all governmental authorities having jurisdiction, to the extent required for such ownership and operation; and (iv) is in compliance with its instrument of corporate formation and by-laws or similar corporate governance rules.

 9.1.2 The execution, delivery and performance of this Agreement by BioCryst and all instruments and documents to be
delivered by BioCryst hereunder (i) are within its corporate power; (ii) are not in contravention of any provision of its instrument of corporate formation and by-laws or similar corporate governance rules; (iii) to BioCryst’s
knowledge do not violate any law or regulation or any order or decree of any court of governmental instrumentality; (iv) do not violate any terms of any indenture, mortgage, deed of trust, lease, agreement, or other instrument to which it is a
party or by which such entity or any of its property is bound, which violation would have a material adverse effect on its financial condition or on its ability to perform its obligations under this Agreement; and (v) do not require any filing
or registration with or the consent or approval of any governmental body, agency, authority or any other Person, which has not been made or obtained previously, including any consent required under the Pre-Existing Third Party License (other than
approvals required under the Regulatory Approvals required for the sale of Licensed Products and filings with regulatory authorities required in connection with Licensed Products). 

9.1.3 This Agreement has been duly executed and delivered by BioCryst and constitutes a legal, valid and binding obligation of
BioCryst, enforceable against it in accordance with its terms, except as such enforceability may be limited by the availability of equitable remedies. 
 9.1.4 To the knowledge of BioCryst, BioCryst has complied with all Legal Requirements in connection with the prosecution of the BioCryst Patents, including without limitation the duty of candor
owed to any patent office under such laws, rules and regulations. 
 9.1.5 BioCryst has the right to grant Mundipharma
the rights and licenses described in this Agreement. 
 9.1.6 BioCryst has not granted any rights with respect to
(i) the Compound or the Licensed Products in the Territory, or (ii) the BioCryst Patents or the BioCryst Know-How in the Field in the Territory, in each case to any person or entity other than Mundipharma. 

9.1.7 There are no claims or investigations pending or threatened against BioCryst or any of its Associates, at law or in equity,
or before or by any governmental authority relating to the matters contemplated under this Agreement that would materially adversely affect BioCryst’s ability to perform its obligations hereunder or thereunder. 

9.1.8 Neither BioCryst nor any of its Associates is under any obligation to any person, contractual or otherwise, that is in
violation of the terms of this Agreement or that would impede the fulfillment of BioCryst’s obligations hereunder. Neither BioCryst nor any of its Associates will enter into any obligation to any person, contractual or otherwise, that is in
violation of the terms of this Agreement or that would impede the fulfillment of BioCryst’s obligations hereunder. 

  
 Page 15

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* *
*” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission 
  

 9.1.9 No employee of BioCryst has been debarred or is the subject of debarment
proceedings by any Regulatory Authority. BioCryst shall not use in connection with its performance of its obligations or duties or its exercise of its rights under this Agreement any employee, consultant or investigator that has been debarred or the
subject or debarment proceedings by any Regulatory Authority. 
 9.1.10 To the knowledge of BioCryst, in accordance with
the terms hereof, BioCryst has not received written notice that the exercise of Mundipharma’s rights granted under this Agreement infringes any Third Party intellectual property rights, and to the knowledge of BioCryst, without inquiry or
investigation, the exercise of Mundipharma’s rights granted under this Agreement, in accordance with the terms hereof, will not infringe or conflict with any Third Party intellectual property rights. 

9.1.11 All material renewal and maintenance fees due as of the Effective Date with respect to the prosecution and maintenance of
the BioCryst Patents and the Trademarks have been paid, except as would not have a material adverse effect on Mundipharma’s rights hereunder. 
 9.1.12 BioCryst has allowed, and will continue to allow, Mundipharma access to all material information in its possession or control (i) containing the results of all preclinical testing and
human clinical testing of Licensed Product in its possession or control and (ii) concerning side effects, injury, toxicity or sensitivity reaction and incidents or severity thereof with respect to Licensed Product. 

9.1.13 There is no action or proceeding related to, nor has BioCryst received any written notice of termination under, the
Pre-Existing Third Party License, and to the knowledge of BioCryst, BioCryst is not in default of any material obligation under the Pre-Existing Third Party License. 
 9.1.14 BioCryst has not licensed or granted any rights in connection with BCX-4208 to any Third Party in the Field, and BioCryst is under no contractual or other obligation to develop BCX-4208 in
the Field. 
 9.1.15 BioCryst has not licensed or granted any rights in connection with the Compound or the Licensed
Products to any Third Party outside the Field, and BioCryst is under no contractual or other obligation to develop the Compound or the Licensed Products outside the Field. 
 9.1.16 To the knowledge of BioCryst, the inventory of the Compound to be purchased by Mundipharma pursuant to Section 4.1.2 is in good useable condition and has been manufactured, packaged,
quality controlled and stored in accordance with all relevant United States Legal Requirements. 
 9.1.17 To the
knowledge of BioCryst, all BioCryst Know-How and data provided to Mundipharma pursuant to the Original Agreement and to be provided to Mundipharma pursuant to this Agreement are materially accurate and complete and have been prepared materially in
accordance with and materially comply with all relevant United States Legal Requirements; provided, however, that the data from clinical studies BCX-203 and BCX-210 which are provided to Mundipharma hereunder have been prepared materially in
accordance with and materially comply with all relevant United States Legal Requirements only through the primary analysis of each completed study. 
 9.1.18 BioCryst will transfer the BioCryst Know-How and data existing at the Effective Date to Mundipharma in accordance with the Transition Assistance Schedule. 

BioCryst acknowledges that Mundipharma is relying, and is entitled to rely, on the foregoing representations, warranties and covenants. 

  
 Page 16

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* *
*” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission 
  

 9.2 Mundipharma’s Representations and Warranties. Mundipharma hereby
represents and warrants the following to BioCryst as of the Effective Date: 
 9.2.1 Mundipharma (i) is a
corporation duly organized, validly existing, and in good standing under the laws of Bermuda, with its principal place of business as indicated in the preamble of this Agreement; (ii) is duly qualified as a limited liability company and in good
standing under the laws of each jurisdiction where ownership or lease of property or the conduct of its business requires such qualification, where the failure to be so qualified would have a material adverse effect on the financial condition of
Mundipharma or the ability of Mundipharma to perform its obligations hereunder; (iii) has the requisite corporate power and authority and the legal right to conduct its business as now conducted and hereafter contemplated to be conducted;
(iv) has all necessary licenses, permits, consents, or approvals from or by, and has made all necessary notices to, all governmental authorities having jurisdiction, to the extent required for such ownership and operation; and (v) is in
compliance with its certificate of formation and limited liability company agreement. 
 9.2.2 The execution, delivery
and performance of this Agreement by Mundipharma and all instruments and documents to be delivered by Mundipharma hereunder: (i) are within the corporate power of Mundipharma; (ii) are not in contravention of any provision of the
certificate of formation or limited liability company agreement of Mundipharma; (iii) to the knowledge of Mundipharma will not violate any law or regulation or any order or decree of any court of governmental instrumentality; (iv) will not
violate the terms of any indenture, mortgage, deed of trust, lease, agreement, or other instrument to which Mundipharma is a party or by which Mundipharma or any of its property is bound, which violation would have an adverse effect on the financial
condition of Mundipharma or on the ability of Mundipharma to perform its obligations hereunder; and (v) do not require any filing or registration with, or the consent or approval of, any governmental body, agency, authority or any other Person,
which has not been made or obtained previously (other than approvals required under the Regulatory Approvals required for the sale of Licensed Products and filings with regulatory authorities required in connection with Licensed Products).

 9.2.3 This Agreement has been duly executed and delivered by Mundipharma and constitutes a legal, valid and binding
obligation of Mundipharma, enforceable against Mundipharma in accordance with its terms, except as such enforceability may be limited by the availability of equitable remedies. 

9.2.4 There are no claims or investigations pending or threatened against Mundipharma or any of its Associates, at law or in
equity, or before or by any governmental authority relating to the matters contemplated under this Agreement that would materially adversely affect Mundipharma’s ability to perform its obligations hereunder or thereunder. 

9.2.5 Neither Mundipharma nor any of its Associates is under any obligation to any person, contractual or otherwise, that is in
violation of the terms of this Agreement or that would impede the fulfillment of Mundipharma’s obligations hereunder. Neither Mundipharma nor any of its Associates will enter into any obligation to any person, contractual or otherwise, that is
in violation of the terms of this Agreement or that would impede the fulfillment of Mundipharma’s obligations hereunder. 

9.2.6 No employee of Mundipharma has been debarred or is the subject of debarment proceedings by any Regulatory Authority.
Mundipharma shall not use in connection with its performance of its obligations or duties or its exercise of its rights under this Agreement (including, without limitation, the Development of any Licensed Products) any employee, consultant or
investigator that has been debarred or the subject or debarment proceedings by any Regulatory Authority. 
 9.2.7
Mundipharma (and its Associates) does not currently own or control rights underlying any PNP Inhibitor other than the Compound, and currently has no current plans to develop or acquire any PNP Inhibitor other than the Compound. 

Mundipharma acknowledges that BioCryst is relying, and is entitled to rely, on the foregoing representations, warranties and covenants. 

9.3 No other Representations. (i) No oral representations or warranties have been made by BioCryst to Mundipharma upon which
Mundipharma is relying in connection with the transactions contemplated by this Agreement; (ii) no oral representations or warranties have been made by Mundipharma to BioCryst upon which BioCryst is relying in connection with the transactions
contemplated by this Agreement; (iii) no written 

  
 Page 17

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* *
*” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission 
  

 
representations or warranties have been made by BioCryst to Mundipharma upon which Mundipharma is relying in connection with the transactions contemplated by this Agreement, other than as set
forth in this Agreement; and (iv) no written representations or warranties have been made by Mundipharma or any of its Associates to BioCryst upon which BioCryst is relying in connection with the transactions contemplated by this Agreement.

 9.4 Disclaimers. EXCEPT AS OTHERWISE PROVIDED IN THIS AGREEMENT, THE FOREGOING REPRESENTATIONS AND WARRANTIES ARE IN
LIEU OF ALL OTHER REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF COMPOUND AND LICENSED PRODUCTS. SPECIFICALLY, (i) BIOCRYST MAKES NO OTHER
REPRESENTATIONS OR WARRANTIES IN RELATION TO THE BIOCRYST PATENTS, THE BIOCRYST KNOW-HOW, THE COMPOUND (INCLUDING COMPOUND AND LICENSED PRODUCTS SUPPLIED HEREUNDER), THE TRADEMARK OR THE LICENSED PRODUCTS, AND (ii) MUNDIPHARMA MAKES NO OTHER
REPRESENTATIONS OR WARRANTIES IN RELATION TO THE MUNDIPHARMA PATENTS, THE MUNDIPHARMA KNOW-HOW, ANY SECONDARY TRADEMARKS, THE COMPOUND OR THE LICENSED PRODUCTS. EXCEPT AS OTHERWISE PROVIDED IN THIS AGREEMENT, BIOCRYST SHALL HAVE NO LIABILITY
WHATSOEVER ARISING OUT OF OR RELATING TO COMPOUND OR LICENSED PRODUCTS SUPPLIED TO MUNDIPHARMA HEREUNDER. 
 ARTICLE 10 -
INDEMNITY AND PRODUCT LIABILITY 
 10.1 Indemnification and Defense by Mundipharma. Mundipharma shall, at its
sole expense, indemnify, defend and hold harmless BioCryst, its licensors under the Pre-Existing Third Party License, Associates and its or their respective officers, directors, agents and employees (the “BioCryst Indemnitees”)
against any Third Party Claim arising out of or resulting from (i) gross negligence, willful misconduct or breach of Legal Requirements relevant to its activities under this Agreement or the Original Agreement (as applicable) by Mundipharma,
its Associates or sublicensees, and/or (ii) Licensed Products manufactured, imported, marketed, distributed or sold by or on behalf of Mundipharma or its Associates, or sublicensees, and all activities related thereto except to the extent that
such Third Party Claim is covered in Section 10.2. 
 10.2 Indemnification and Defense by BioCryst. BioCryst
shall, at its sole expense, indemnify, defend and hold harmless Mundipharma, its Associates and its or their respective officers, directors, agents and employees (the “Mundipharma Indemnitees”) against any Third Party Claim arising
out of or resulting from gross negligence, willful misconduct or breach of Legal Requirements relevant to its activities under this Agreement or the Original Agreement (as applicable) by BioCryst, its Associates or sublicensees (other than
Mundipharma or its Associates). 
 10.3 Defense Procedures. BioCryst and Mundipharma shall notify each other
promptly in writing upon learning of any Third Party Claim in respect of which indemnification may be sought under Section 10.1 or Section 10.2, as the case may be. The indemnifying Party shall actively defend against (or settle if
appropriate) every Third Party Claim using counsel approved by the indemnified Party, such approval not to be unreasonably withheld or delayed, shall promptly inform the indemnified Party and its attorneys of all developments concerning the
indemnified Party and shall generally consult with the indemnified Party regarding the strategy of the defense of any Third Party Claim. To the extent allowed by law, the BioCryst Indemnitees and the Mundipharma Indemnitees, as the case may be,
shall reasonably cooperate with the indemnifying Party in defending or settling any such Third Party Claim. No settlement of any Third Party Claim for which indemnification is sought, shall be made without the prior written approval of the
indemnifying Party. The indemnifying Party will have sole control over the defense and/or settlement, subject to the BioCryst Indemnitees’ and Mundipharma Indemnitees’, as the case may be, right to select and use their own counsel at their
sole cost and expense. 
 10.4 Insurance. Each Party shall obtain and shall, as long as Mundipharma, directly or
indirectly, is undertaking the Mundipharma Trials Plan or Developing, Commercializing, manufacturing, marketing, testing or distributing the Licensed Products and for at least * * * (* * *) years thereafter, maintain at such Party’s sole cost
and expense product liability insurance, or shall set up, at its sole cost and expense, a self insurance arrangement, and such insurance shall meet the following requirements: 
 10.4.1 the insurance shall insure such Party against all liability related to the Licensed Products (whether such Party’s liability arises from its own conduct, that of its Associates,
sublicensees or distributors or by virtue of its participation in this Agreement), including liability for bodily injury, property damage, wrongful death, and any contractual indemnity obligations imposed by this Agreement; and 

 

  
 Page 18

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* *
*” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission 
  

 10.4.2 the insurance shall have a minimum limit of * * * U.S. Dollars ($* * *)
per occurrence with an annual aggregate limit of not less than seven million U.S. Dollars ($* * *). 
 Each Party shall provide the other with a
Certificate of Insurance evidencing such insurance coverage upon the request of the other Party. Each Party shall be entitled to substitute a program of self-insurance for all or a part of such Party’s Third Party insurance required hereunder
at its sole option. 
 10.5 Survival. Neither the expiration nor termination of this Agreement shall in any way affect
the provisions of this Article 10 or relieve or discharge any Party with respect thereto. The Parties understand and agree that the representations, warranties, covenants and agreements, including without limitation those set forth in this Article
10, shall survive without limitation. 
 10.6 Disclaimer of Liability for Consequential Damages. IN NO EVENT SHALL ANY
PARTY OR ANY OF ITS RESPECTIVE AFFILIATES BE LIABLE UNDER THIS AGREEMENT FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, WHETHER IN CONTRACT, WARRANTY, TORT, NEGLIGENCE, STRICT LIABILITY OR OTHERWISE, INCLUDING, BUT NOT LIMITED TO, LOSS
OF PROFITS OR REVENUE, SUFFERED BY BIOCRYST OR MUNDIPHARMA, RESPECTIVELY, UNDER THIS AGREEMENT, EXCEPT (A) TO THE EXTENT OF ANY SUCH DAMAGES PAID TO A THIRD PARTY AS PART OF A THIRD PARTY CLAIM WHICH IS INDEMNIFIABLE HEREUNDER, AND (B) IN
THE EVENT OF AN INTENTIONAL AND WILLFUL BREACH IN BAD FAITH OF ANY REPRESENTATION, WARRANTY, COVENANT OR AGREEMENT BY BIOCRYST OR MUNDIPHARMA OR THEIR RESPECTIVE AFFILIATES (AS THE CASE MAY BE) OF THIS AGREEMENT. 

ARTICLE 11 - TERM AND TERMINATION 
 11.1 Term. 
 11.1.1 This Agreement shall commence on and as of the
Effective Date and shall continue for the Commercial Life of the Licensed Products, unless terminated earlier as set forth below (the “Term”). As used in this Section 11.1.1, “Commercial Life” shall mean as
long as there is any development or Commercialization of the Licensed Products in the Territory by Mundipharma, its Associates or its permitted Third Party sublicensees or distributors. 

11.2 Termination by Parties. 
 11.2.1 By Either Party. Either Party may terminate this Agreement immediately on written notice to the other Party in the event that the Pre-Existing Third Party License expires, subject always to
Mundipharma’s rights pursuant to Section 5.4. 
 11.2.2 Termination by BioCryst. BioCryst may terminate this
Agreement as follows: 
 11.2.2.1 If Mundipharma is generally unable to meet its debts when due, or makes a general
assignment for the benefit of creditors, or there shall have been appointed a receiver, trustee or other custodian for Mundipharma for all or a substantial part of its assets, or any case or proceeding shall have been commenced or other action taken
by or against Mundipharma in bankruptcy or seeking the reorganization, liquidation, dissolution or winding-up of Mundipharma or any other relief under any bankruptcy, insolvency, reorganization or other similar act or Legal Requirements, and any
such event (other than any such event which shall have been instituted by Mundipharma) shall have continued for sixty (60) days undismissed, unstayed, unbonded and undischarged, then BioCryst may, upon notice to Mundipharma, terminate this
Agreement. 

  
 Page 19

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* *
*” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission 
  

 11.2.2.2 BioCryst may notify Mundipharma that a Material Default by Mundipharma
has occurred, in which case BioCryst may terminate this Agreement, without prejudice to Mundipharma’s right to dispute the notified Material Default in accordance with the dispute resolution procedures set out in Article 12 and Exhibit
A. For purposes of example and not limitation, Mundipharma’s challenge or any challenge by a Third Party acting on behalf of Mundipharma to the validity or enforceability of or opposition by such persons to any BioCryst Patents shall be
deemed to be a Material Default of this Agreement and shall give rise to BioCryst’s right to terminate this Agreement pursuant to this Section 11.2.2.2. 
 11.2.3 Termination by Mundipharma. Mundipharma may terminate this Agreement as follows: 
 11.2.3.1 If BioCryst is generally unable to meet its debts when due, or makes a general assignment for the benefit of creditors, or there shall have been appointed a receiver, trustee or other
custodian for BioCryst for all or a substantial part of its assets, or any case or proceeding shall have been commenced or other action taken by or against BioCryst in bankruptcy or seeking the reorganization, liquidation, dissolution or winding-up
of BioCryst or any other relief under any bankruptcy, insolvency, reorganization or other similar act or Legal Requirements, and any such event (other than any such event which shall have been instituted by BioCryst) shall have continued for sixty
(60) days undismissed, unstayed, unbonded and undischarged, then Mundipharma may, upon notice to BioCryst, terminate this Agreement. 
 11.2.3.2 Mundipharma may notify BioCryst that a Material Default by BioCryst has occurred, in which case Mundipharma may terminate this Agreement, without prejudice to BioCryst’s right to
dispute the notified Material Default in accordance with the dispute resolution procedures set out in Article 12 and Exhibit A. 
 11.2.3.3 Mundipharma may, in its sole discretion upon sixty (60) days’ prior written notice to BioCryst, terminate this Agreement; provided that Mundipharma shall pay to BioCryst the
applicable Payments and Royalties accruing on or prior to the termination date. 
 11.2.3.4 Mundipharma may terminate
this Agreement immediately on written notice to BioCryst in the event that a Regulatory Approval in the Territory is cancelled, withdrawn or suspended as a result of a serious safety issue of the Licensed Products. 

11.2.3.5 Mundipharma may terminate this Agreement immediately on written notice to BioCryst in the event that the Pre-Existing
Third Party License terminates. * * *. 
 11.3 Rights and Obligations of Parties upon Term Expiration or Termination.

 11.3.1 Any termination (i) shall be without prejudice to a Party’s right to damage or legal redress that
a Party hereto may be entitled to for any breach or Material Default of this Agreement, provided that neither Mundipharma nor BioCryst will incur any liability to the other Party by rightfully terminating this Agreement as provided in
Section 11.2, whether for loss of goodwill, anticipated profits or otherwise, (ii) shall not release a Party hereto from any indebtedness, liability or other obligation incurred hereunder by such Party prior to the date of termination or
expiration, (iii) shall allow both parties to immediately exercise their audit rights under Section 6.6 whether or not such Party had already exercised such rights in that calendar year, and (iv) shall be without prejudice to a
Party’s right to dispute the existence of a Material Default notified by the other Party as the basis for termination, in which event the termination of this Agreement shall be held in abeyance pending the outcome of the dispute resolution
procedures set out in Article 12. 
 11.3.2 In case of termination of this Agreement, each Party shall promptly pay to
the other Party all amounts due. To the extent not otherwise required by Legal Requirements, in the event of termination under Sections 11.2.1, 11.2.2, 11.2.3.3, 11.2.3.4 and 11.2.3.5, (i) Mundipharma shall use all reasonable efforts to return
to BioCryst all documents (including copies) of any kind concerning the Compound or the Licensed Products received from BioCryst and (ii) BioCryst shall be entitled to a non-exclusive license to use Mundipharma’s Know-how in connection
with the Development and Commercialization of Licensed Products in the Field upon payment of one hundred and fifty percent (150%) of Mundipharma’s and its Associates’ costs of generating such Mundipharma Know-how; provided, however,
that BioCryst’s obligation to pay for use of the data shall not include the use by BioCryst of safety information which may have an effect on PNP inhibitors generally. 

  
 Page 20

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* *
*” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission 
  

 11.3.3 In case of termination of this Agreement under Sections 11.2.1, 11.2.2,
11.2.3.3, 11.2.3.4 and 11.2.3.5, the licenses set forth in Article 2 shall terminate. 
 11.3.4 In case of termination of
this Agreement by BioCryst under Section 11.2.2 or termination by Mundipharma under Sections 11.2.3.3 or 11.2.3.4 Mundipharma shall promptly assign all of its Trademark applications or registrations in the Territory to BioCryst free of charge.
In case of termination for any reason other than under Sections 11.2.2, 11.2.3.3 or 11.2.3.4, Mundipharma will assign to BioCryst all right, title, and interest in and to any such Trademark applications or registrations, including the goodwill
symbolized thereby, promptly upon receipt of BioCryst’s payment of Mundipharma’s reasonable cost of acquiring, maintaining and transferring such Trademark applications or registrations. 

11.3.5 Within * * * (* * *) Business Days from the date of notice of termination of this Agreement under Sections 11.2.1, 11.2.2,
11.2.3.3 and 11.2.3.4, Mundipharma shall commence all action necessary or advisable to transfer to BioCryst or such entity as BioCryst may designate, all Regulatory Approvals relating to the Licensed Products, which are then held by Mundipharma or
its Associates in the Territory. Mundipharma’s obligation hereunder shall include, but not be limited to, the execution and delivery of all necessary documents in a form reasonably acceptable to BioCryst in order to complete and fully implement
the definitive transfer and assignment thereof to BioCryst, and to register all such transfers to BioCryst with a Regulatory Authority, including but not limited to all IND and NDA applications and Marketing Authorizations. Such transfer shall be
made free of charge to BioCryst, except as set forth in Section 11.3.8. 
 11.3.6 The Parties hereby agree that as
soon as any transfer pursuant to Section 11.3.5 of a Regulatory Approval has been registered with a Regulatory Authority, BioCryst or its designee will be the sole owner of said Regulatory Approval. 

11.3.7 Promptly after notice of any termination, Mundipharma shall provide BioCryst with copies of all relevant Third Party
sublicenses, agreements with clinical research organizations and other Third Party agreements relating to Licensed Products hereunder, and allow BioCryst * * * (* * *) days from the date of such delivery to choose whether to assume any or all of
such contracts to the extent allowed by the applicable contract or law. Mundipharma shall, subject to its ability to do so, assign to BioCryst those Third Party agreements BioCryst chooses to assume. 

11.3.8 If this Agreement is terminated pursuant to 11.2.3.2 as a result of BioCryst’s uncured Material Breach, then without
prejudice to Sections 11.3.3. 11.3.4 and 11.3.5, BioCryst shall reimburse Mundipharma for Mundipharma’s reasonable out of pocket expenses incurred in the transfer of rights and documents required hereunder, which expenses shall be pre-approved
by BioCryst before Mundipharma makes the transfers incurring such expenses. 
 11.3.9 Upon termination of this Agreement,
Sections 4.7, 5.1, 5.2, 6.2 (to the extent that the payment obligation accrues prior to termination), 6.3 (to the extent that the payment obligation accrues prior to termination), 6.4, 6.5, 6.6, 6.8, 11.2.3.3 (to the extent that the Royalties,
and/or Payments accrue prior to termination) 11.3, 13.1, 13.7, 13.8, 13.9, and Articles 1, 10, and 12 (and the Exhibits attached thereto) shall survive without limitation. 
 ARTICLE 12 - DISPUTE RESOLUTION AND GOVERNING LAW 
 12.1
Disputes. Unless otherwise set forth in this Agreement, in the event of a dispute arising under this Agreement between the Parties and/or their Associates, such dispute shall be referred to the respective executive officers of the Parties
designated below, or their successors, for good faith negotiations attempting to resolve the dispute. The designated executive officers are as follows: 
  

			
	For Mundipharma:	  	Regional Director, Europe
	For BioCryst:	  	President and CEO

  
 Page 21

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* *
*” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission 
  

 12.2 Dispute Resolution. 

12.2.1 Any dispute or claim arising out of or relating to this Agreement (other than with respect to patent, copyright, trademark
or trade secret rights), or to the breach, termination, or validity of this Agreement, will be resolved as follows: the officers of each Party referred to in Section 12.1 above will meet to attempt to resolve such dispute by good faith
negotiations. If such officers cannot resolve the dispute within * * * days after a Party requests such a meeting, then each Party will attempt in good faith to settle the dispute by mediation pursuant to Section 12.2.2. 

12.2.2 The mediation of any dispute is to be administered by JAMS or such other mediator as may be mutually agreed to by the
Parties. If mediation is unsuccessful within * * * days after the Parties request mediation pursuant to this Section 12.2.2, the Parties may then resort to the alternative dispute resolution procedures set forth on Exhibit A. 

12.2.3 Notwithstanding anything to the contrary in Sections 12.2.1 or 12.2.2, if either Party in its sole judgment believes that
any such dispute could cause it irreparable harm, such Party (a) will be entitled to seek equitable relief in order to avoid such irreparable harm, and (b) will not be required to follow the procedures set forth in Sections 12.2.1.

 12.3 Governing Law. This Agreement is made in accordance with and shall be governed and construed under the laws of
New York, without regard to its choice of law principles. The parties hereby irrevocably submit to the jurisdiction of the courts located in the County and State of New York. 
 ARTICLE 13 - MISCELLANEOUS 
 13.1 Mutual Release. 

13.1.1 Release of BioCryst. Upon execution of this Agreement, each of Mundipharma and any predecessors, successors and Associates,
and each of their respective officers, directors, employees and agents, shall release and discharge, to the fullest extent of the law, each of BioCryst and any predecessors, successors and Associates, and each of their respective officers,
directors, employees and agents, from any and all claims, debts, sums of money, contracts, agreements, obligations, damages, and liabilities of any kind or nature, including attorneys’ fees, costs, and expenses of every kind and however
denominated, including interest thereon, arising out of or in connection with the Original Agreement; provided, however, that the foregoing release shall not apply to release or discharge the performance of any obligations under this Agreement.

 13.1.2 Release of Mundipharma. Upon execution of this Agreement, each of BioCryst and any predecessors, successors and
Associates, and each of their respective officers, directors, employees and agents, shall release and discharge, to the fullest extent of the law, each of Mundipharma and any predecessors, successors and Associates, and each of their respective
officers, directors, employees and agents, from any and all claims, debts, sums of money, contracts, agreements, obligations, damages, and liabilities of any kind or nature, including attorneys’ fees, costs, and expenses of every kind and
however denominated, including interest thereon, arising out of or in connection with the Original Agreement; provided, however, that the foregoing release shall not apply to release or discharge the performance of any obligations under this
Agreement 
 13.2 Covenants. Mundipharma covenants that, during the term of this Agreement, it shall carry out the
Development and Commercialization of the Licensed Products and its other obligations and activities hereunder in accordance with (i) the terms of this Agreement, (ii) accepted applicable pharmaceutical industry codes of practice and
(iii) applicable Legal Requirements. 
 13.3 Non-Compete. * * *. 

  
 Page 22

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* *
*” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission 
  

 13.4 Delay of payment. If Mundipharma fails to make a timely payment pursuant to
the terms of this Agreement, interest shall accrue on the past due amount at a rate of interest equal to the 30-day U.S. Dollar London Inter-Bank Offering Rate (“LIBOR”) in the case of payments denominated in U.S. Dollars as
published in The Financial Times, effective for the date on which the payment was due; provided, that if such failure to pay continues for more than * * * (* * *) days, the applicable rate of interest shall be the 30-day LIBOR rate effective for the
date on which payment was due, plus * * * percent (* * *%) for the entire period of delinquency. All interest due pursuant to this Section shall be computed on an actual/360 basis. 

13.5 Assignment. This Agreement shall not be assignable in part or in whole (by operation of law or otherwise) by any Party
without the prior written consent of the other; provided, however, that BioCryst, without notice and at any time for any reason, may assign this Agreement in whole or in part to (i) any of its Associates who agree to be bound by the terms and
conditions of this Agreement or (ii) any successor of BioCryst by merger or sale of all or substantially all of its business assets to which this Agreement relates, and provided further that Mundipharma, without the written consent of BioCryst,
may assign this Agreement in whole or in part to any of its Associates with exactly the same or greater financial standing and resources as Mundipharma and who agree to be bound by the terms and conditions of this Agreement. 

13.6 Pre-Existing Third Party License. Mundipharma acknowledges and agrees that the terms of this Agreement are subject in all
respects to the terms of the Pre-Existing Third Party License, which has been previously provided to Mundipharma. Mundipharma further agrees that (i) the licensors under the Pre-Existing Third Party License retained certain rights, which are
not granted to Mundipharma hereunder; (ii) such licensors shall be deemed to be Third Party beneficiaries of this Agreement, entitled to enforce BioCryst’s rights hereunder; (iii) all Confidential Information provided to BioCryst
hereunder may be shared with such licensors; and (iv) Mundipharma shall assist BioCryst in complying with its obligations (including but not limited to recordkeeping and the provision of information to such licensors) under the Pre-Existing
Third Party License. BioCryst agrees to update Mundipharma on the activities of BioCryst’s licensors under the Pre-Existing Third Party License, the U.S. government, the National Cancer Institute and the New Zealand Foundation for Research,
Science and Technology in connection with the Compound to the extent that BioCryst is aware of such activities. 
 13.7 Press
Releases and External Communications. Neither Party shall issue press releases or make public announcements relating to this Agreement without the other Party’s prior written approval, which approval shall not be unreasonably withheld or
delayed; provided, however, that nothing in this Section shall impair either Party’s compliance with any requirements of the Securities and Exchange Commission or the national securities exchange or other stock market on which such Party’s
securities are traded; and, provided further, that BioCryst may issue external media and investor communications related to the transactions contemplated by this agreement if such external media communications are previously approved by Mundipharma,
which approval shall not be unreasonably withheld or delayed. In connection with any filing by either Party of a copy of this Agreement with the Securities and Exchange Commission (or the national securities exchange or other stock market on which
such Party’s securities are traded), the filing Party shall endeavor to obtain confidential treatment of economic and trade secret information. Reasonably in advance of filing, the filing Party shall provide to the other Party a copy of the
proposed filing and the Parties shall work cooperatively in good faith, taking into consideration the other Party’s suggestions, regarding the information for which the filing Party will seek to obtain confidential treatment. Notwithstanding
the foregoing, BioCryst shall be entitled to make public disclosures regarding the status of Mundipharma’s Development work provided that no Confidential Information of Mundipharma is disclosed. 

13.8 Use of Name. Neither Party shall use the other Party’s name or trademarks for publicity or advertising purposes, except
with the prior written consent of the other Party. 
 13.9 Notices. Any notices, requests, reports, approvals,
designations, responses, or other communications provided for in this Agreement to be made by either of the Parties to the other shall be in writing and shall be sufficiently given when made by prepaid registered or certified air mail or by an
internationally reputable overnight courier addressed to the other at its address set forth below. Any such notice or communication may also be given by hand or telecommunicated. Either Party may by like notice specify an address to which notices
and communications shall thereafter be sent. Any such notice, instruction or communication shall be deemed to have been delivered upon receipt if delivered by hand, three (3) Business Days after it is sent by registered or certified mail,
return receipt requested, postage prepaid, one (1) Business Day after it is sent via an 

  
 Page 23

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* *
*” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission 
  

 
internationally reputable overnight courier service, or when transmitted with electronic confirmation of receipt, if transmitted by facsimile (if such transmission is on a Business Day;
otherwise, on the next Business Day following such transmission). 
  

			
	In the case of BioCryst:	  	With a required copy to:
	 BioCryst Pharmaceuticals, Inc.
 4505 Emperor Boulevard
 Durham, North Carolina 27703

 
 Attention: President & CEO

 
 Facsimile No.: 919-859-1314
	  	 Proskauer Rose LLP
 11 Times Square
 New York, New York 10036

 
 Attention: Daryn Grossman, Esq.

 
 Facsimile No.: (212) 969-2900

		
	In the case of Mundipharma:	  	With required copies to:
	 14 Par-la-Ville Road
 Hamilton HMJX Bermuda
  
 Attention: General Manager
  
 Facsimile No.: +1 441 292 1472
	  	 Mundipharma International Limited
 Cambridge Science Park
 Milton Road

Cambridge CB4 0GW
  

Attention: (1) Regional Director, Europe, and
  

(2) European General Counsel
  

Facsimile No.: +44 1223 424442

 13.10 Effect of Waiver. The waiver from time to time by either of the Parties of any of their
respective rights or privileges or their failure to exercise any remedy shall not operate or be construed as a continuing waiver of same or of any other of such Party’s rights, privileges or remedies provided in this Agreement. 

13.11 Effect of Partial Invalidity. If any term, covenant or condition of this Agreement or the application thereof to any Party
or circumstances shall, to any extent, be held to be invalid or unenforceable, then (i) the remainder of this Agreement, or the application of such term, covenant or condition to parties or circumstances other than those as to which it is held
invalid or unenforceable, shall not be affected thereby and each term, covenant or condition of this Agreement shall be valid and be enforced to the fullest extent permitted by law; and (ii) the Parties hereto covenant and agree to renegotiate
any such term, covenant or application thereof in good faith in order to provide a reasonably acceptable alternative to the term, covenant or condition of this Agreement or the application thereof that is invalid or unenforceable. 

13.12 Force Majeure. Each Party will be excused from the performance of its obligations under this Agreement to the extent that
such performance is prevented by a Force Majeure Event (as defined below) and the non-performing Party promptly provides written notice to the other Party of such inability and of the period for which such inability is expected to continue. Such
excused performance will be continued so long as the condition constituting a Force Majeure Event continues and the non-performing Party takes reasonable efforts to remove or cure the condition. For purposes of this Agreement, a Force Majeure Event
means conditions caused by occurrences beyond the control of the Party affected, including an act of God, an act, pronouncement, omission or delay in acting by any Governmental Authority or Regulatory Authority or the other Party, war, an act of
war, terrorism, insurrection, riot, civil commotion, epidemic, failure or default of public utilities or common carriers, shortages of raw materials or other supplies necessary for Mundipharma’s Third Party manufacturer to manufacture the
Licensed Products, sabotage, labor strike, lockout, labor disturbance, embargo, fire, explosion, earthquake, flood, storm or like catastrophe (each a “Force Majeure Event”). 

13.13 Entire Agreement; Amendment. This Agreement (including the Schedules and Exhibits hereto) sets forth all the covenants,
promises, agreements, warranties, representations, conditions and understandings 

  
 Page 24

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* *
*” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission 
  

 
between the Parties hereto and supersedes and terminates all prior agreements and understanding between the Parties (including but not limited to the Original Agreement). There are no covenants,
promises, agreements, warranties, representations, conditions or understandings, either oral or written, between them concerning the subject matter hereof, other than as are herein set forth. No subsequent alteration, amendment, change or addition
to this Agreement shall be binding upon the Parties hereto unless reduced to writing and signed by the respective authorized officers of the Parties. 
 13.14 Status of Parties. The status of each Party hereunder is that of an independent contractor. No provision of this Agreement shall be construed to place the Parties in the relationship of
partners or joint venturers. Neither Party is, and neither will represent itself to be, an agent, representative or employee of the other Party, and neither Party has any right or authority to obligate the other in any manner or thing whatsoever. No
third parties shall be entitled to rely upon the terms and conditions of this Agreement. 
 13.15 Further Assurances.
After the Effective Date, the Parties shall and, to the extent this Agreement expressly imposes obligations on its Associates, each Party shall cause such Associates to, from time to time, execute and deliver such additional instruments, documents,
conveyances or assurances and take such other action as shall be necessary or other reasonably requested by the other Party, to confirm and assume the rights and obligations provided for in this Agreement. 

13.16 Performance by Associates. Each of Mundipharma and BioCryst acknowledges that certain obligations under this Agreement may
be performed by Associates of Mundipharma and BioCryst. Each of Mundipharma and BioCryst guarantees the performance of this Agreement by any of its Associates, and shall remain responsible therefor. Any Associate of Mundipharma or BioCryst to which
rights are extended or which performs any of the obligations required of the respective Party hereunder will be deemed to have accepted and be bound by the relevant terms and conditions of this Agreement, including the dispute resolution procedures
set forth in Section 12.2. 
 13.17 Intellectual Property. The Parties acknowledge and agree that the BioCryst
Patents and BioCryst Know-How licensed under this Agreement are “intellectual property” within the meaning of Section 101(35(A)) of Title 11 of the U.S. Code (the “Bankruptcy Code”), and that this Agreement is an
executory contract governed by Section 365(n) of the Bankruptcy Code in the event that a bankruptcy proceeding is commenced involving BioCryst. 
 13.18 Counterparts; Facsimile Signature. This Agreement may be executed in counterparts, each of which counterparts, when so executed and delivered, will be deemed to be an original, and both of
which counterparts, taken together, will constitute one and the same instrument even if both Parties have not executed the same counterpart. Signatures provided by facsimile transmission will be deemed to be original signatures. 

  
 Page 25

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* *
*” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission 
  

 IN WITNESS WHEREOF the parties hereto have executed this Agreement by their proper
officers on the date and year first above written. 
  

			
	BIOCRYST PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Alane Barnes

	Name:	 	Alane Barnes
	Title:	 	VP, General Counsel
	
	MUNDIPHARMA INTERNATIONAL CORPORATION LIMITED
		
	By:	 	 /s/ Douglas Docherty

	Name:	 	Douglas Docherty
	Title:	 	General Manager

  
 Page 26

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00200-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00200-of-00352.parquet"}]]